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This work reports the continued search for new antibiotics in the relatively under 
investigated region of KwaZulu-Natal, South Africa. A soil bacterium designated strain N8 
with antibacterial activity against both Gram-positive and Gram-negative bacteria was 
isolated from a poultry farm in Pietermaritzburg, South Africa. The organism was one of 
approximately 2600 strains isolated from various habitats in the KwaZulu-Natal midlands, 
South Africa during an actinomycete screening programme. The highest number of 
antimicrobially-active isolates came from a forest soil site whereas the lowest number was 
present in a riparian soil.  
 
Morphological, physiological and cultural characteristics indicated that strain N8 belonged 
in the genus Intrasporangium. In the literature, members of this actinomycete genus have 
not been associated previously with antibiotic production. Studies on the influence of 
different nutritional compounds on antibiotic production showed that the highest 
antibacterial activities were obtained when glycerol at 1% (w/v) was used as sole carbon 
source in the presence of mineral trace elements. 
 
Using solvent extraction and various chromatographic techniques, the antibiotic produced 
by strain N8 was recovered from the fermentation broth. The use of a three-solvent 
system, petroleum ether: acetone: ethyl acetate enhanced the separation of the antibiotic 
complex in broth. Bioassay results established that the antibacterial agent was in the ethyl 
acetate fraction (EAF) and chromatographic methods were used in its purification. The 
chromatographic methods used were: flash column chromatography (FCC), thin-layer 
chromatography (TLC), and Harrison research chromatotron (HRC). Further purification 
was carried out by reverse phase high performance liquid chromatography (HPLC). Most 
of the inactive, coloured material was removed from the antibiotic extract by FCC, while 
TLC chromatograms run using a range of the most polar to the least polar solvent systems 
[SS1 (most polar) – SS5 (least polar)] showed best separation of EAF with SS2. TLC 
chromatograms using SS2 usually showed 3 bands. Bioautograms of SS2-separated EAF 
revealed that the antibiotic activity was located in the region with an Rf value of 0.56 – 
0.64. The Harrison research chromatotron technique also gave good separation of the 
EAF sample. Preparative HPLC was used as the final purification step for most of the EAF 
samples. Although, a number of peaks were observed during isocratic-HPLC (IHPLC) 
runs, they were not as clearly separated as those obtained with gradient-HPLC (GHPLC). 
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Three major peaks PI, PII and PIII with elution times of 3.56 min, 4.53 min and 23.06 min 
respectively were revealed under GHPLC runs with decreasing concentrations (100% – 
50%) of methanol in water. Methanol concentrations between 50% and 70% in water were 
considered the optimum GHPLC mobile phases. 
 
Since these chromatographic methods were all time consuming, required large volumes of 
solvents, and resulted in low yields of the antibiotic, an alternative procedure producing 
better results was sought. This led to the development of a procedure combining a three-
solvent extraction system with a pH precipitation process which efficiently recovered the 
antibiotic in solid/crystal form. Using this procedure, sufficient quantities of the antibiotic 
were recovered from the fermentation broth to permit a degree of structural elucidation. 
Two types of crystals (brown and pink-yellow in colour) were obtained and their chemical 
natures established by means of 1H- and GCOSY- nuclear magnetic resonance (NMR) 
and liquid chromatography-mass spectrometry (LC-MS). On further LC-MS analysis, the 
brown crystals appeared to be a protein and since it did not show inhibitory activity against 
any of the test organisms, no further studies were carried out on it. The pink-yellow 
crystals when suspended in a minimal volume of methanol showed inhibitory activity 
against S. marcescens confirming that the antibiotic activity resided therein. The LC-MS 
spectrum of these crystals showed a prominent/base peak at 304.2724 [mass to charge 
ratio (m/z) in positive mode]. The elemental composition of this compound suggests a 
molecular formula close to C16H36N2O3 with a molar mass of 304.4686 g/mol. No existing 
name could be assigned to it from the database of known natural compounds. Hence, the 
possibility that it is a novel antimicrobial compound cannot be excluded.  
 
Characterisation of the antimicrobial substance using GC-MS revealed that it contained at 
least seven components (A – G). These components were then subjected to mass 
spectrum analysis and their retention indices compared to computer database listings of 
known compounds. Components A and B were regarded as representing one compound 
(possibly isomers) since they have the same molecular weight and formula. Their different 
retention indices strongly suggest they are indeed isomers. Thus a total of six different 
compounds were detected in the extract by GC-MS and the molecular formulae assigned 
to them include: C6H10O (A and B); C6H12O2 (C); C9H14O (D); C8H7N (E); C21H44 (F); and 
C12H14N2O (G). Since only low probability matches were obtained for A – F and as the 
sample could not be recovered from the analyser, they were not studied further. The 
closest match (71% probability) with substances listed in the computer database of natural 
compounds was for compound G (C12H14N2O) which was thus provisionally identified as 
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N-acetyltryptamine. A structurally related compound known as melatonin is attributed with 
the ability to inhibit tumour growth in vivo and in vitro.  
 
Attempts were made to assign a chemical structure to the antibiotic produced by strain N8 
using all the data available. The indications are that it is a tryptamine, the chemical 
structure of which is postulated to be:  
 
 
In order to monitor the antimicrobial activity of the antibiotic produced by strain N8, 
bioassays were conducted after all major steps during the isolation and characterization 
processes. The antimicrobial activity of the pink-yellow crystals was confirmed on the test 
organisms used during the primary screening phase, namely, Escherichia coli, 
Pseudomonas fluorescens, Serratia marcescens, Staphylococcus aureus, Enterococcus 
faecalis and Xanthomonas campestris pv. campestris, and the yeast Candida utilis, 
indicating that the crude substance had maintained its inhibitory activity against Gram-
positive and Gram-negative bacteria, and the yeast tested. The study was extended to 
include investigations into the use of combinations of the GHPLC separated peaks of the 
antibiotic (PI, PII and PIII) to improve the efficacy of growth inhibition of the test pathogens 
for possible use in chemotherapy. Data from these studies showed that PI inhibited the 
growth of E. coli and X. campestris pv. campestris while PII and PIII inhibited the growth of 
the latter organism and also that of S. marcescens. Individually, the peaks showed no 
growth inhibition on Pseudomonas fluorescens but the combination PI+PII+PIII was 
antimicrobially effective. In all cases, the use of combinations was significantly more 
effective than the use of any single component alone. For example, the combination of 
GHPLC PI and PII had a greater growth inhibitory effect (synergic action) against Serratia 
marcescens than did either alone; the inhibition-zone diameter being double (30mm) that 
caused by the single peaks (15mm) against S. marcescens. Likewise mixing PI and PIII 
resulted in a much improved action against X. campestris pv. campestris. These findings 
may meet the current call by many scientists that all infectious diseases should be treated 
with a combination of two antibiotics with different mechanisms of action in order to 
counter the serious problem of emerging bacterial resistance. 
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Since the antibiotic isolated during this study showed activity against both mammalian and 
plant pathogenic bacteria it is hoped that this work will encourage further investigation in 
this field in South Africa. The results obtained should impact on the pharmaceutical 
industry as well as agriculture and will, hopefully, help curb both plant and human 
infectious diseases in our African communities. This study also confirmed that KwaZulu-
Natal soils do harbour rare actinomycetes that produce novel antimicrobial compounds. 
 




The experimental work described in this thesis was carried out in the School of 
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 “A perfect storm is brewing in infectious diseases” …Scheld, 2003*. 
“Infectious diseases physicians are alarmed by the prospect that effective antibiotics 
may not be available to treat seriously ill patients in the near future. There simply aren‟t 
enough new drugs in the pharmaceutical pipeline to keep pace with drug resistant 
bacterial infections, so-called „superbugs.” … Dalovisio, 2004# 
 
Of the thousands of antibiotics discovered over the past ten decades, none has as yet 
produced a definitive answer to the apparent question of „microbial resistance‟. 
According to Richard Laing, an expert on medicine policy at the World Health 
Organization in Geneva, “The relative lack of research on anti-microbials is a matter of 
concern and there is clearly a potential risk, due to growing antibiotic resistance, that 
there won‟t be any effective anti-microbial available in the future” (Hirschler and 
Ransdell, 2004). The Infectious Diseases Society of America, representing more than 
7,500 physicians and scientists, said in a recent report that a “perfect storm” was 
brewing in infectious diseases (Hirschler and Ransdell, 2004). Microbial resistance to 
treatment could bring the world back to a pre-antibiotic age (Schmidt, 2004). 
 
Many drug companies in the United States and Europe first made their fortunes from 
antibiotics discovered through natural products screening, mostly of soil 
microorganisms. Eventually the collections, or libraries, of organisms assembled in the 
1940s and 50s began failing to produce new antibiotics. By the 1970s and 80s, the big 
pharmaceutical companies started making modifications to the existing basic classes of 
antibiotics instead of searching for new ones from nature (Erickson, 2003).  
 
_________________________ 
*Scheld, W.M. (2003b). Potential NIAID solutions to the problem posed by emerging and resistant 
microorganisms. Letter to Infectious Diseases Society of America 
#
Dalovisio, J.R. (2004):  Bad bugs, No drugs: As antibiotic discovery stagnates, a public health crisis 
brews. Infectious Diseases Society of America report 
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New versions of antibiotics introduced are described as if they were succeeding 
generations of a family. Thus, penicillin G and V for example, are called first-generation 
antibiotics, whereas later examples of the basic penicillin structure have been called 
second-generation, third-generation, etc. We are currently in the fourth generation of 
antibiotics about 60 years after their discovery and first use (Walsh and Wright, 2005). 
 
This modification approach has failed because resistance is developed easily to these 
antibiotics by bacteria which have had billions of years of evolution to cope with harsh 
environments and can withstand any chemical attack (Projan and Bradford, 2007). This 
failure is evident in the obvious innovation gap between 1960 and 2000 (Table 1.1). 
During that period, only three new classes of antibiotics were approved (Walsh and 
Wright, 2005). 
 
Table 1.1 Classes of antibiotics and their year of approval for clinical use 
Classes of antibiotics Year approved 











Source: Gill (2008) 
 
Over the last decade, it has become clear that the widespread emergence of acquired 
resistance to antibiotics in bacteria still constitutes a serious threat to public health, 
hence the need to search for antibiotics with new modes of action (Salyers and Whitt, 
2005, Spellberg et al., 2008; Fischbach and Walsh, 2009). 
 
The multinational drug companies complain of many problems: the lack of chemical 
diversity against targets, the difficulty of differentiating new antibiotics without 
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embarking on huge trials, the financial risks of proving novelty and the habit of 
reserving truly new antibiotics by hospitals for emergencies (Schmidt, 2004). Of the 
more than 400 agents described since 1998, only nine new antibiotics have been 
approved, of which just two, Linezolid (oxazolidinone) and Telithromycin (ketolide) had 
a novel mechanism of action (Gill, 2008). The 2004 annual reports of major drug 
companies list a mere five new antibiotics in development. These figures paint a 
gloomy picture of the fight against infectious diseases (Gill, 2008). Economies of scale 
usually make it possible for big pharmaceutical companies to produce antibiotics more 
cheaply for big markets. Thus, the major research inputs on antibiotics relate directly to 
those diseases occurring within the developed countries and not to those in the 
developing countries where the need is greatest (Smith, 1986). Although the range of 
antibiotic therapy is broad, there are still no effective antibiotics for many infecting and 
disease-producing microorganisms, particularly the diseases predominant in the 
developing world (Miyo, 2006)*. 
 
As hospitals struggle to deal with superbugs, such as methicillin resistant 
Staphylococcus aureus (MRSA), and with antibiotic resistance in pathogenic organisms 
in general, the search for new antibiotics has a new sense of urgency. The search for 
new antibiotics follows certain basic principles (Chopra et al., 1997): 
 the first is an account of the geographical distribution of the antibiotic-producing 
microorganisms 
 the second is that the producers should be rapidly and properly identified 
 the third is concerned with the isolation and purification of the active compounds 
 fourthly structural elucidation of the compounds is necessary to demonstrate 
their novelty 
 These requirements can be extended to include investigations into the use of 
combinations of the compounds to improve the efficacy of growth inhibition of 
the test pathogens for use in chemotherapy since this is the current trend rather 




  ______________________ 
* Personal communication. Higher education research training attended at the Institute of Development 
Management, Gaborone, Botswana in September, 2006.  
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The present investigation has followed these principles in the search for new antibiotics 
from local sources. The thesis is divided into six chapters: Chapter 1 is a review of the 
relevant literature; Chapter 2 focuses on the materials and methods used; Chapter 3 
covers the isolation and geographical distribution of the antibiotic-producing strains 
isolated and their subsequent identification. Chapters 4 and 5 describe respectively the 
purification and structural elucidation of the antibiotic complex isolated; Chapter 6 
focuses on the synergistic antimicrobial activities of the compounds produced. Each 
chapter starts with an introduction and links with the chapter on the materials and 
methods used in the investigation. To avoid unnecessary repetitions all references are 
placed together in a general „References‟ section at the back of the thesis. The thesis 
starts with an introduction and ends with an overview. The overview reflects on the 
achievement (or otherwise) of the original objectives and gives some recommendations 
for future research. 
 
1.1.1 Aims and objectives 
KwaZulu-Natal soils have been reported as a potential source of novel antibiotic 
producing microorganisms (Baecker and Ryan, 1987; Ntuli, 1994; Okudoh and Wallis, 
2007). For example, the organism, Streptomyces natalensis, first used in industrial 
production of Pimaricin, was originally isolated from Natal soils (Baecker and Ryan, 
1987). 
The main aim of this study was to isolate and identify antibiotic-producing non-
streptomycetous actinomycetes from soils and other habitats in the KwaZulu-Natal 
midlands. The next undertaking was to purify and characterize the most promising of 
the many strains isolated, viz. Intrasporangium stain N8 isolated from a poultry farm in 
Pietermaritzburg, South Africa.  
 
Other objectives were: 
 To optimize production of the antibiotic by manipulation of the fermentation 
parameters and to test its inhibitory efficacy against selected human and plant 
pathogens. 
 To isolate and purify the biologically active substance(s) using thin layer 
chromatography (TLC), Harrison research chromatotron and high performance 
liquid chromatography (HPLC). 
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 To elucidate, as far as possible, the structure of the biologically active 
substance(s) using nuclear magnetic resonance (NMR), liquid 
chromatography/mass spectrometry (LCMS), gas chromatography/mass 
spectrometry (GCMS) and other physical techniques. 
 To investigate the use of combinations of the active substances to improve the 
efficacy of inhibition of the test pathogens and to compare their synergistic 
activities with some of the established antibiotics. 
It is hoped that the results of this study will impact on the pharmaceutical industry as 
well as on agriculture and will contribute to the control/curbing of both plant and human 
infectious diseases in sub-Saharan African communities. 
 
1.2 What are antibiotics? 
The term antibiotic was first introduced by Selman Waksman in 1947 to describe, “A 
chemical substance derived from microorganisms, which has the capacity of inhibiting 
growth, and even destroying other microorganisms in dilute solutions” (Waksman, 
1947). According to Gottlieb and Shaw (1967) antibiotics are “organic substances that 
are produced by microorganisms and are harmful at low concentrations to growth and 
metabolic activities of other organisms”. This definition was limited by Lancini and 
Parenti in 1982 to special inhibitory products of low molecular weight and excluded 
enzymes, lactic acid, ethanol and other similar substances that prevent growth of some 
microorganisms. 
 
Debate over the definition of antibiotics has continued. Forsdyke in 2000 included 
synthetic molecules like AZT in his definition on the basis that they are derivatives of 
microbial products. According to him an antibiotic is “a chemical of natural or synthetic 
origin, which at low concentrations inhibits microorganisms of some type within a host 
organism, while not unacceptably interfering with the life of that organism”. Carlberg 
(2000) opposed the use of „synthetic origin‟ in the definition and suggested that AZT 
and most of the other agents used to treat HIV infections should be referred to as 
antiviral agents, antiviral drugs or perhaps antimicrobics, because they are synthetic 
molecules, and the term „antibiotic‟ should be reserved for such familiar compounds as 
penicillin and streptomycin. 
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Most microbiologists are more comfortable with definitions that exclude any synthetic 
product (Okudoh, 2001) and the present work should be read in that context. 
 
1.3 Microbial sources of antibiotics – General overview 
Over 10000 different antibiotics have been isolated from cultures of gram-positive and 
gram-negative bacteria and of filamentous fungi. However, only about 100 of these 
have been commercially used to treat human, animal and plant diseases. The reason 
for this is that only compounds with selective toxicity can be used clinically (Walsh, G. 
2003). 
 
Many medically useful antibiotics are produced by members of the genus Bacillus e.g. 
polymyxin and bacitracin produced by B. polymyxa and B. licheniformis respectively. 
The classical β-lactam antibiotics, penicillin and cephalosporin, are synthesized by the 
filamentous fungi Penicillium and Cephalosporium, but can also be produced by some 
actinomycetes and other bacteria. However, the actinomycetes, mainly Streptomyces 
species, are responsible for the synthesis of more than 60% of the known antibiotics 
while a further 15% are made by members of the related actinomycetes: 
Micromonospora, Actinomadura, Actinoplanes, Nocardia, Streptosporangium, 
Streptoverticillium and Thermoactinomyces (Okudoh, 2001). Thus, almost all 
commercially used antibiotics are produced by three groups of microorganisms – 
Streptomyces, Bacillus and the filamentous fungi (Miyadoh, 1993). 
 
These organisms all have in common that they live in soil and they form some sort of 
spore or resting structure. It is not known why these microorganisms produce 
antibiotics, but the answer may be that it affords them some nutritional or spatial 
advantage in their habitat by antagonizing the competition; or it acts as some sort of 
hormone or signal molecule associated with sporulation or dormancy or germination 
(Todar, 2009). Actinomycetes are the producers of most of the clinical important 
antibiotics (Miyadoh, 1993) and thus will be discussed in more detail. 
 
1.3.1 Antibiotic formation by actinomycetes 
Actinomycetes are mainly gram-positive bacteria that form branching filaments or 
hyphae and asexual spores. They are generally aerobic and have a high percentage of 
G+C content (about 60 – 70%). They include a very diverse group of organisms such 
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as streptomycetes, nocardioform and corynebacterium with lots of properties in 
common (Okudoh, 2001).  
 
Actinomycetes are important from a medical point of view. They constitute a nuisance 
when they decompose rubber products, grow in aviation fuel and produce odorous 
substances that pollute water supplies, or grow in sewage treatment plants where they 
form thick clogging foams. In contrast, they are very useful when they produce clinically 
important antibiotics. Close to 50% of the known antimicrobial products are produced 
by actinomycetes (Miyadoh, 1993).  
 
The discovery of new molecules from actinomycetes marked an epoch in antibiotic 
research and subsequent developments in antibiotic chemotherapy. Since the 
discovery of streptomycin, a large number of antibiotics, including major therapeutic 
agents such as aminoglycosides, chloramphenicol, tetracyclines, macrolides and more 
recently, members of the β-lactam cephamycin group, have been isolated from cultures 
of Streptomyces and Streptoverticillium (Atlas of actinomycetes, The society for 
actinomycetes, Japan 1997). 
 
Streptomyces species have long been recognised as the best antibiotic-producing 
bacteria and several strains have been rigorously screened by the pharmaceutical 
industry.Consequently, the chances of isolating a new compound have substantially 
diminished. More current efforts are concentrated on unusual or difficult to isolate 
microbes, mostly non-streptomycetous actinomycetes or rare actinomycetes (Bull et al., 
2000; Lazzarini et al., 2000). 
 
1.3.2 Antibiotic formation by rare actinomycetes 
As more new antibiotics were discovered, the chances of finding novel antimicrobial 
leads among conventional actinomycetes dwindled. The focus of industrial screening 
therefore moved to markers of less exploited genera of rare actinomycetes such as 
Actinomadura, Actinoplanes, Amycolatopsis, Dactylosporangium, Kibdelosporangium, 
Microbispora, Micromonospora, Planobispora, Streptosporangium and 
Planomonospora (Lazzarini et al., 2000).  
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The importance of the rare actinomycetes is demonstrated by the fact that many of the 
successful antibiotics on the market are produced by such actinomycetes; rifamycins 
are produced by Amycolatopsis mediterranei, erythromycin by Saccharopolyspora 
erythraea, teicoplanin by Actinoplanes teichomyceticus, vancomycin by Amycolatopsis 
orientalis and gentamicin from Micromonopsora purpurea (Lancini and Lorenzetti, 
1993). 
 
The richest group of rare actinomycetes is represented by Actinoplanes strains which 
have been extensively isolated by exploiting the mobility of their spores and their 
chemotactic behaviour to different saline or organic solutions (Palleroni, 1980; 
Hayakawa et al., 1991; Lancini and Lorenzetti, 1993). More than 120 antibiotics have 
been reported from Actinoplanes strains. Amino acid derivatives, such as peptides and 
depsipeptides are prevalent and among these compounds some are of clinical 
relevance such as teicoplanin, from Actinoplanes teichomyceticus ATCC 31121 
(Bardone et al., 1978) and ramoplanin from Actinoplanes sp. ATCC 33076 (Ciabatti 
and Cavalleri, 1989).  
 
Another group of rare actinomycetes isolated on a massive scale in recent years are 
those belonging to the genus Micromonospora, which is considered to encompass the 
second largest group of culturable actinomycetes in soil. Their isolation has been 
mainly based on the use of antibiotics such as gentamicin and novobiocin as selective 
agents (Williams and Wellington, 1982) or deleterious agents such as phenol and 
chlorhexidine gluconate solutions (Hayakawa et al., 1991). Important antibiotics 
produced by Micromonospora strains include the aminocyclitols, such as gentamicins; 
sisomicin; fortimicin; macrolides, such as the mycinamicins and rosamicins and 
polysaccharide antibiotics such as everninomycin (Lancini and Lorenzetti, 1993).  
 
Among the different genera and families belonging to the order Actinomycetales, the 
genus Streptomyces is followed – in terms of the number of strains producing 
antibiotics - by the family Micromonosporaceae (mainly Micromonospora and 
Actinoplanes), the family Pseudonocardiaceae (mainly Amycolatopsis, 
Sacharopolyspora and Sacharothrix) and the family Thermomonosporaceae (mainly 
Actinomadura), the family Nocardiaceae (Nocardia and related genera), the family 
Streptosporangiaceae (mainly Streptosporangium) [Lazzarini et al., 2000]. The relative 
distribution of the producing strains among rare actinomycetes is shown in Figure 1.1. 
 




Fig. 1.1 Relative distribution of producing strains among rare actinomycetes: 1,578 producers of 
bioactive compounds described in the antibiotic literature database (ABL) database are divided into 
different families and genera according to the recent classification published in the Atlas of Actinomycetes 
Japan. 
 
The focus organism in the present study, Intrasporangium, is also a rare actinomycete, 
with only one type species Intrasporangium calvum. The organism produces branching 
mycelium which has a definite tendency to fragment, non-motile sporangiospores, and 
also sporangia intercalary in the mycelial hyphae. Intrasporangium is classified as a 
member of the family Actinoplanaceae. To the author‟s knowledge, no antibiotic 
formation has been earlier reported for Intrasporangium sp. 
 
1.4 Groups of antibiotics – General overview 
Various schemes of grouping antibiotics have been proposed, none of which has been 
adopted (Lancini et al., 1995). These include:  
 grouping on the basis of the producer organism. However, some organisms 
may produce several antibiotics, e.g., the production of penicillin-N and 
cephalosporin C by Cephalosporium acremonium (Berdy, 1980). 
 grouping according to the route of biosynthesis. This grouping failed because 
several biosynthetic routes often have much commonality (Okudoh, 2001). 
 grouping according to modes of action, i.e., whether they are cell-wall or cell 
membrane inhibitors, inhibit protein or nucleic acid synthesis, or interfere with 
the whole system of cellular metabolism. However, several mechanisms of 
action may operate simultaneously making such classification difficult (Berdy, 
1974).  
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 Currently, those natural and semisynthetic antibiotics that have a common 
chemical structure are grouped into one “class” and named after the member 
first discovered or after a principal chemical property (Todar, 2009). The 
chemical grouping is very useful in practice, as the components of one group 
usually share many biological properties and also it enables the accommodation 
of new compounds as they are discovered (Lancini et al., 1995). In this work, 
the groupings according to chemical structure and modes of action will be 
followed. 
 
1.4.1 Grouping according to chemical structure 
Antibiotics are a very heterogeneous group chemically (Lancini and Parenti, 1982). 
They include substances of molecular weights from 150 to 5000 daltons. The 
molecules may contain only hydrogen and carbon, or, more commonly, carbon, 
oxygen, hydrogen and nitrogen. Other molecules also contain sulphur, phosphorus or 
halogen atoms. Almost all organic structures are represented (aliphatic chains, alicyclic 
chains, aromatic rings, heterocycles, carbohydrates, polypeptides, etc.). The chemical 
structures of some commonly used antibiotics are shown in Figure 1.2 and reveal this 
diversity in structures. For example, amphotericin B, diflucan, flucytosine and 
griseofulvin are all antifungal antibiotics but their structures are very different. Likewise, 
ampicillin, vancomycin, streptomycin, erythromycin, tetracycline, etc., are all 
antibacterial antibiotics with diverse structures. In fact, the only property that all 
antibiotics have in common is that they are organic solids, which is obvious from their 
definition as products of microbial metabolism (Lancini and Parenti, 1982). 
 
There are thirteen main groups of antibiotics based on chemical structure (Berdy, 
1974). However, the number of groups may increase to fifteen if the semi-synthetic 
penicillins and tetracyclines are included (Todar, 2009). A summary of chemical groups 
of antibiotics and their properties, including their biological source and mode of action, 
is shown in Table 1.2. 
 
 




Fig. 1.2 Examples of structures of some commonly used antibiotics. Note the diversity of structures. Source: Salyers and Whitt, (2005). 
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Fig. 1.2 continued  
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Fig. 1.2 continued  
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Table 1.2 Chemical groups of antibiotics and their properties 
Chemical group Examples Biological source Spectrum Principal chemical property Mode of action 
Beta-lactams       
 Penicillins 
 
Penicillin G  Penicillium notatum  Gram-positive bacteria β-lactam ring (Lancini et al, 1995; 
Ophardt, 2003) 
Inhibits steps in cell wall 
(peptidoglycan) synthesis and 
murein assembly 
 Cephalosporins Cephalothin Cephalosporium 
species 
" " " 
Semisynthetic β- lactams      
 Aminopenicillins Ampicillin, Amoxycillin  Gram-positive and Gram-
negative bacteria 
β-lactam ring (Lancini et al, 1995; 
Ophardt, 2003) 
Inhibits steps in cell wall 
(peptidoglycan) synthesis and 
murein assembly 
 Clavulanic acid  Clavamox is clavulanic 
acid plus Amoxycillin 
Streptomyces 
clavuligerus 
“ “ Suicide inhibitor of beta-
lactamases 
  Monobactams Aztreonam Chromobacter 
violaceum 
“ “ Inhibits steps in cell wall 
(peptidoglycan) synthesis and 
murein assembly 
 Carboxypenems Imipenem Streptomyces cattleya “ “ “ 
 Peptides      
 Polypeptides Polymyxin Bacillus polymyxa Gram-negative bacteria Peptide linked D and L amino acids 
(Wilson et al., 2004) 
Damages cytoplasmic 
membranes 




Gram-positive bacteria “ Inhibits steps in murein 
(peptidoglycan) biosynthesis 
and assembly 





Peptide linked D and L amino acids 
with carbohydrate (Wilson et al., 
2004, IUPAC, 2009) 
Inhibits steps in murein 
(peptidoglycan) biosynthesis 
and assembly 
 Lincomycins Clindamycin Streptomyces 
lincolnensis 
Gram-positive and Gram-
negative bacteria esp. 
anaerobic Bacteroides 
6,8-dideoxy-6-aminooctose 
lincosamine (Spizek and Rezanka, 
2004) 
Inhibits translation (protein 
synthesis) 
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Chemical group Examples Biological source Spectrum Principal chemical property Mode of action 




Amino sugars in a glycosidic 
linkage (Dale-Skinner and Bonev, 
2008) 
Inhibit translation (protein 
synthesis) 
  Gentamicin Micromonospora 
species 
Gram-positive and Gram-
negative bacteria esp. 
Pseudomonas 
“ “ 
 Macrolides Erythromycin Streptomyces erythreus Gram-positive bacteria, 
Gram-negative bacteria 
not enterics, Neisseria, 
Legionella, Mycoplasma 
Lactone rings linked through 
glycoside bonds with amino sugars 
(Todar, 2009) 
“ 
 Polyenes Amphotericin B Streptomyces nodosus Fungi (Histoplasma) Macrocyclic ring with conjugated 
double bonds and amino sugars 
(Hammond and Lambert, 1978) 
Inactivates membranes 
containing sterols 
  Nystatin 
Streptomyces noursei 
Fungi (Candida) “ “ 






Naphto and benzoquinone nuclei 
derivatives (Lancini et al., 1995) 
Inhibits transcription 
(eubacterial RNA polymerase) 




carboxamide (IUPAC, 2009) 
Inhibit translation (protein 
synthesis) 




derivatives of polycyclic naphthone 
carboxide ((IUPAC, 2009) 
“ 




Nitrobenzene derivative of 
dichloroacetic acid (Prescott et al., 
2000) 
“ 
“, Same as above; Source: Todar, (2009), original table modified by grouping the semisynthetic β-lactams, the peptides and also by adding the principal chemical 
properties. The synthetic antibiotics such as quinolones, fluoroquinolones, isoniazid, etc., are omitted from this table. 
Table 1.2 continued 
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The present review will focus on β-lactams, polypeptides and tetracycline groups of 
antibiotics as they are among the most clinically successful. 
 
1.4.1.1 The β-Lactams 
Penicillins as well as cephalosporins are called beta-lactam antibiotics and are 
characterized by three fundamental structural requirements: the fused beta-lactam 
structure, a free carboxyl acid group (shown in red bottom right), and one or more 
substituted amino acid side chains (shown in black). The lactam structure (Fig. 1.3) 
can also be viewed as the covalent bonding of pieces of two amino acids - cysteine 
(blue) and valine (red) [Ophardt, 2003]. 
 
 
Fig. 1.3 Penicillin showing beta-lactam structure: Lactam (a four-atom ring) fused with a thiazolidine 
(a five-atom ring). Source: Ophardt (2003). 
 
These antibiotics are the products of two genera of fungi, Penicillium and 
Cephalosporium, and are correspondingly represented by the penicillins and 
cephalosporins (Fig. 1.4). Two other classes of beta-lactams are the carbapenems and 
monobactams. The latter are particularly useful for the treatment of allergic individuals. 
A person who becomes allergic to penicillin usually becomes allergic to the 
cephalosporins and the carbapenems as well. Such individuals can still be treated with 
the monobactams, which are structurally different (Fig. 1.4) so as not to induce allergy 
(Coffman, 2010). 
 
The era of extensive use of antibiotics in medicine began in 1942 when penicillin G was 
introduced into clinical practice (Lancini et al., 1995). However, it has several 
shortcomings and is effective only against gram-positive bacteria. It may be broken 
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down in the stomach by gastric acids and is poorly and irregularly absorbed into the 
blood stream. In addition many disease producing staphylococci are able to produce an 
enzyme (β-lactamase) capable of inactivating penicillin-G. Various semisynthetic 




Fig. 1.4 The structure of members of the penicillin family (β-lactams). Clockwise: penicillin, 
cephalosporin, monobactam, carbapenem. They are characterized by a four-member β-lactam ring as 
shown in the diagram. Penicillin G (Benzylpenicillin) where R = an ethyl phenyl group is the most potent of 
all penicillin derivatives. Source: Salyers and Whitt, (2005). 
 
The breakthrough that led to the preparation of a thousand semisynthetic penicillins 
was the isolation of 6-aminopenicillanic acid (6-APA) [Lancini and Parenti, 1982]. 
Starting with 6-APA many structural analogs of penicillin V (e.g. phenethicillin, 
propicillin, azidocillin) were synthesised according to the reaction scheme shown in 
Figure 1.5. 
 
Powerful electron-attracting groups attached to the amino acid side chain (position 6) 
such as in phenethicillin prevent acid attack. A bulky group attached to the amino acid 
side chain provides steric hindrance which interferes with the lactamase enzyme 
attachment which would deactivate the penicillins. Finally if the polar character is 
increased as in ampicillin or carbenicillin, there is a greater activity against Gram-
negative bacteria (Ophardt, 2003). 
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Similar to penicillins, many semisynthetic cephalosporins were prepared through the 
isolation of 7-aminocephalosporanic acid (7-ACA) [Fig.1.6B]. Some of the derivatives 
prepared include cephalothin, cephaloridine, cephapirin, cephalexin, cefazolin, etc. 




Fig. 1.5 Scheme of synthesis of semisynthetic penicillins from 6-APA and the derivatives of 
penicillin V.  Source: Lancini and Parenti, 1982. 
 
The second- and third-generation cephalosporins were characterised by their 
enhanced antibacterial activity obtained mainly by the choice of a suitable substituent 
at the amide chain in position 7 combined with a substituent in position 3 compatible 
with good pharmacokinetics. The presence of a methoxyl group at position 7 enhanced 
the stability of the cephalosporins to a broad variety of Gram-negative 
cephalosporinases, especially those produced by Bacteroides species. Cefoxitin was 
the first compound with a 7-methoxyl group to be developed for clinical use. The 
cephalosporins which were absorbed orally generally had a simple methoxyl group at 
the 3 position. Alterations in the side chain at the 3 position of the cephalosporin 
molecule also enhanced the serum protein binding and renal excretion of the 
compound (Gorbach et al., 2004). Cephalosporins unlike penicillins had the potential of 
being modified not only at the side chains but also in position 3 of the nucleus, where 
the acetoxyl group can be easily eliminated or substituted without loss of activity 
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Fig. 1.6 A, Cephalosporin C; B, 7-aminocephalosporanic acid (7-ACA): Source: Lancini and 
Parenti, 1982. 
 
The beta lactam antibiotics are stereochemically related to D-alanyl-D-alanine (Fig. 
1.7) which is a substrate for the last step in peptidoglycan synthesis, the final cross-
linking between peptide side chains. Penicillins bind to and inhibit the carboxypeptidase 
and transpeptidase enzymes that are required for this step in peptidoglycan 
biosynthesis. Beta lactam antibiotics are bactericidal and require that cells be actively 
growing in order to exert their toxicity (Todar, 2009).  
 
Specifically, the cross linking of peptides on the mucosaccharide chains is prevented. If 
cell walls are improperly made they allow water to flow into the cell causing it to burst. 
Resemblances between a segment of penicillin structure and the backbone of a 
peptide chain have been used to explain the mechanism of action of beta-lactam 
antibiotics (Ophardt, 2003). 
 
Gram-positive bacteria possess a thick cell wall composed of a cellulose-like structural 
sugar polymer covalently bound to short peptide units in layers. The polysaccharide 
portion of the peptidoglycan structure is made of repeating units of N-
acetylglucosamine linked β-1, 4 to N-acetylmuramic acid (NAG-NAM). The peptide 
varies, but begins with L-Ala and ends with D-Ala. In the middle is a dibasic amino acid, 
diaminopimelate (DAP). DAP (orange) provides a linkage to the D-Ala (gray) residue 
on an adjacent peptide (Fig. 1.7). Synthesis of the bacterial cell wall is completed when 
a cross link between two peptide chains attached to polysaccharide backbones is 
formed. The cross linking is catalyzed by the enzyme transpeptidase. First the terminal 
alanine from each peptide is hydrolyzed and secondly one alanine is joined to lysine 
through an amide bond (Ophardt, 2003).  
 
 
     
20 
 
Fig. 1.7 Comparison of structures of D-alanine-D-alanine (left) and beta-lactam antibiotic 
penicillin (right); Follow the trace of the red oxygen and blue nitrogen atoms. Source: Ophardt, (2003). 
 
Penicillin binds at the active site of the transpeptidase enzyme that cross-links the 
peptidoglycan strands. It does this by mimicking the D-alanyl-D-alanine residues that 
would normally bind to this site. Penicillin irreversibly inhibits the enzyme 
transpeptidase by reacting with a serine residue in the transpeptidase. This reaction is 
irreversible and so the growth of the bacterial cell wall is inhibited. Since mammalian 
cells do not have the same type of cell walls, penicillin specifically inhibits only bacterial 
cell wall synthesis (Ophardt, 2003). 
 
Different beta-lactams differ in their spectrum of activity and their effect on Gram-
negative rods, as well as in their toxicity, stability in the human body, rate of clearance 
from blood, whether they can be taken orally, ability to cross the blood-brain barrier, 
and susceptibility to bacterial beta-lactamases (Jacoby and Carreras, 1990).  
 
Natural penicillins, such as penicillin G (benzyl penicillin), penicillin V (phenoxymethyl 
penicillin) and penicillin K (n-Heptyl penicillin) are effective against streptococci, 
gonococci and staphylococci, except where resistance has developed. They are 
considered narrow spectrum since they are not effective against Gram-negative rods. 
Penicillins with enlarged spectra of activity were obtained by substitution of the phenyl 
group of penicillin G with certain heterocyclic rings. Many derivatives have been 
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prepared including: ampicillin (D-α-aminobenzylpenicillin), cyclacillin, epicillin, 
amoxicillin, pivampicillin, etc. Ampicillin with its high level of efficacy inhibited not only 
the bacteria sensitive to penicillin G, but also most strains of E. coli, Salmonella, and 
Shigella. However, it was not considered a broad-spectrum antibiotic, as it was inactive 
against most strains of Klebsiella, Enterobacter, and Proteus and totally inactive 
against Pseudomonas and S. aureus (Lancini et al., 1995). 
 
 Although nontoxic, penicillins occasionally cause death when administered to persons 
who are allergic to them. In the U.S. there are 300 - 500 deaths annually due to 
penicillin allergy. In allergic individuals the beta lactam molecule attaches to a serum 
protein and initiates an IgE-mediated inflammatory response (Todar, 2009). 
 
Cephalosporins have a low toxicity and a somewhat broader spectrum than natural 
penicillins. They are often used as penicillin substitutes against Gram-negative bacteria 
and in surgical prophylaxis. They are subject to degradation by some bacterial beta-
lactamases, but they tend to be resistant to beta-lactamases from S. aureus (Widmer, 
2008). 
 
1.4.1.2 The polypeptides 
The term peptide is normally used for compounds that contain a small number of amino 
acid residues whilst the term polypeptide is used for larger compounds with relative 
molecular values of 300 or more. Proteins are more complex polypeptides with relative 
molecular values greater than 2000 (Thomas, 2007). Among the most powerful 
bactericidal antibiotics are those that possess a peptide structure. Many of them have 
been isolated, but unfortunately their clinical uses have been limited by their 
undesirable side reactions, particularly renal toxicity. Examples include: bacitracin, 
vancomycin, actinomycin, polymyxin B and polymyxin E (colistin) (Wilson et al., 2004). 
Most of them cannot be administered orally due to lack of systemic activity. However, 
the polymyxins (Fig. 1.8A) are very effective against Gram-positive bacteria and 
therefore useful in severe urethral tract infections (Zuzana et al., 2009). 
 
Polypeptide antibiotics variously possess a number of interesting and often unique 
characteristics; (a) they frequently consist of several structurally similar but chemically 
distinct entities isolated from a single source; (b) most of them are cyclic with a few 
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exceptions (e.g., the gramicidins, glycopeptides); (c) they frequently contain D-amino 
acids not found in higher plants and animals; and (d) many of them contain non-amino 
acid moieties, such as heterocycles, fatty acids, sugars, etc. Polypeptide antibiotics 
may be acidic, basic, zwitterionic, or neutral depending on the number of free carbonyl 





Fig.1.8 Examples of polypeptide antibiotics: A, Polymyxin B; B, Fundamental structure of bacitracin 
and the N-terminal thiazoline ring (R=R1, R2 or R3) to give bacitracin A, B, and C respectively. Asn, 
Asparagine; Asp, Aspartic acid, Glu, Glutamic acid; His, Histidine; Leu, Leucine; Lys, Lysine; Orn, 
Ornithine, Phe, Phenylalanine; Val, Valine. Source: Wilson et al., (2004).  
 
1.4.1.3 The Tetracyclines 
The tetracyclines consist of eight related antibiotics which are all natural products of 
Streptomyces spp., although some can now be produced semisynthetically or 
synthetically. Tetracycline, chlortetracycline and doxycycline are the best known. The 




     
23 
Streptomyces aureofaciens. This was followed two years later by oxytetracycline, 
isolated from Streptomyces rimosus, and in 1952 by tetracycline (Fig. 1.9). The latter 
was originally synthesised by catalytic hydrogenation of chlortetracycline and later by 
fermentation first by growth of Streptomyces aureofaciens in a medium without chlorine 
and later by fermentation of Streptomyces strains that were able to produce it directly. 
All three of these compounds demonstrated cross-resistance and had very similar 
spectra of activity (Todar, 2009). 
 
The tetracyclines are broad-spectrum antibiotics with a wide range of activity against 
both Gram-positive and Gram-negative bacteria. Pseudomonas aeruginosa is less 
sensitive but is generally susceptible to tetracycline concentrations that are obtainable 
in the bladder (Lancini et al., 1995). 
 
 
Fig. 1.9 Natural tetracyclines showing their broad spectrum activities: Source: Lancini and 
Parenti (1982). 
 
Comparisons of the activities of the natural tetracyclines and of different derivatives 
thereof have shown that positions 5, 6, 7 and 9 can have different substituents without 
any substantial loss of activity. Removal of the hydroxyl group at position 6, with 
rhodium as catalyst, conferred greater stability to tetracycline but led to the inversion of 
the configuration of the methyl group and resulted in decreased activity. Substitutions 
in positions 7 and 9 led to the development of minocycline (Fig. 1.10) which is active 
both in vitro and in vivo against strains of S. aureus, Enterococcus and E. coli that are 
resistant to tetracycline. However since this achievement most efforts have been 
without success. Only a few laboratories are still working on new tetracyclines 
(Gorbach et al., 2004). 
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 Minocycline 
Fig. 1.10 Structure of the tetracycline derivative minocyline: Source: Gorbach et al., (2004).  
 
The tetracyclines have a remarkably low toxicity and minimal side effects when taken 
by animals. The combination of their broad spectrum and low toxicity has led to their 
overuse and misuse by the medical community and the wide-spread development of 
resistance has reduced their effectiveness. Nonetheless, tetracyclines still have some 
important uses, such as the use of doxycycline in the treatment of Lyme disease 
(Todar, 2009).  
 
1.4.2 Grouping according to mode of action  
Several authors have grouped antibiotics based on the site of action in the 
microorganism (Hammond and Lambert, 1978; Franklin and Snow, 1981; Lancini and 
Parenti, 1982; Lancini et al, 1995; Todar, 2009). These groupings include:  
A. Inhibitors of cell wall synthesis  
B. Disruptors of cell membranes  
C  Inhibitors of protein synthesis  
D. Inhibitors of nucleic acid synthesis 
 
A summary of the biological groups of antibiotics and their properties, including their 
spectra of activity and mode of action, is shown in Table 1.3. Refer to section 1.6 for 
more detailed discussion on the mechanism of action of these antibiotics. 
 
1.5 Antimicrobial activity of antibiotics 
Antibiotics may have a cidal (killing) effect or a static (inhibitory) effect on a range of 
microbes (Todar, 2009). If a reaction such as cell wall synthesis is blocked irreversibly, 
the antibiotic is bactericidal, ultimately leading to the death of the organism. The 
irreversible step in cell wall synthesis is the opening of the existing wall to allow cell 
growth (Mayberry, 2004)  
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Table 1.3 Biological groups of antibiotics and their properties 
Biological group Examples Spectrum Mode of action 
1. Inhibitors of cell wall 
synthesis 
 
Beta-lactams (Penicillins, Cephalosporins, 
Monobactams, Thienamycins); 
Beta-lactamase inhibitors (e.g., clavulanic acid) 
 
Gram-positive bacteria and 
Gram-negative bacteria 
β-lactams inhibit steps in cell wall (peptidoglycan) synthesis 
and murein assembly (Todar, 2009) 
Clavulanic acid is a suicide inhibitor of beta-lactamases 
(Reading and Farmer, 1981) 
 Cycloserine, Fosfomycin (Phosphonomycin), 
Vancomycin, Bacitracin, Ristocetin 
Gram-positive and Gram-
negative bacteria 
Inhibit steps in cell wall (peptidoglycan) synthesis and murein 
assembly (Lancini et al., 1995) 
2. Disruptors of cell membranes 
 
Lipopeptides (Polymyxin B, Polymyxin E (colistin), 
circulin); 
Polyenes (Amphotericin B, Nystatin); 
Ionophores [linear peptides (gramicidins), cyclic 
peptides (alamethacin), cyclodepsipeptides 
(valinomycin, enniantins), macrotetralides, 
sideromycins]; 
Tyrocidin 
Gram-negative bacteria,  
 
Antitmour, Fungi 
Damage cytoplasmic membranes (Franklin and Snow, 1981) 
Polyenes inactivate membranes containing sterols (Franklin 
and Snow, 1981) 
3. Inhibitors of protein synthesis 
 
30S ribosome-binding antibiotic 
Aminoglycosides (Streptomycin), Amikacin, 
Gentamycin, Kanamycin, Neomycin, Tobramycin,  
Tetracyclines  
 




negative bacteria, Protozoa 
Inhibit translation (protein synthesis) [Todar, 2009] 
 50S ribosome-binding antibiotics 
Chloramphenicol, Clindamycin, Furadantin, 
Fusidic acid, Lincomycin, Nitrofuran, Puromycin, 
Kirromycins, Quinopristin/Dalfopristin, 
Spectinomycin, Macrolides (Azithromycin, 
Dirithromycin, Clarithromycin, Erythromycin) 
Gram-positive and Gram-
negative bacteria, Protozoa, 
Fungi 
Inhibit translation (protein synthesis) [Tritz, 2000] 
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Biological group Examples Spectrum Mode of action 
 
4. Inhibitors of Nucleic acid 
synthesis 
 
The quinolones (nalidixic acid - first generation, 
norfloxacin, ciprofloxacin - second generation), 
Showdomycin, Actinomycin D, Adriamycin, 
Daunomycin, Chromomycin, Azaserine, Alanosine, 
Hadacidin, Mitomycins, Bleomycins, Ansamycins 
(rifamycins, streptovaricins, tolipomycins, 
halomycins), Streptolidigin. 
 
Antitumour agents Inhibit transcription (eubacterial RNA polymerase) [Tritz, 
2000] 
     
 
Table 1.3 continued 
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If a reaction is blocked reversibly, the antibiotic is bacteriostatic, suppressing the 
growth of the organism to give the infected individual‟s immune system a chance to 
catch up (Mayberry, 2004). Some examples of bactericidal antibiotics in clinical use 
are shown in Table 1.4. 
 
Table 1.4 Bactericidal versus bacteriostatic antibiotics in clinical use 
Bactericidal antibiotics Bacteriostatic 
All cell wall synthesis inhibitors 
-Beta-Lactams, bacitracin, fosfomycin, 






All other antibiotics are bacteriostatic 
All DNA synthesis inhibitors 
- Nalidixic acid, quinolones, novobiocin 
All RNA synthesis inhibitors 
- Rifampicin, Actinomycin D 
All membrane-active antibiotics 
- Polymyxins, gramicidins 
Only one of protein synthesis inhibitors  
- Aminoglycosides (spectinomycin) 
Source: Mayberry, (2004). 
 
1.5.1 Selective toxicity 
Most clinically useful antibiotics exhibit their selective toxicity by specifically blocking 
one or another type of bacterial macromolecular synthesis (e.g. protein, nucleic acid 
or cell wall synthesis) -- acting on targets that are not present or accessible in 
animal/human cells. For example, polyene antibiotics act exclusively on cells which 
have sterols in their cytoplasmic membrane and thus affect yeasts, fungi and animal 
cells but have no effect on most bacteria (Franklin and Snow, 1981). Biochemical 
pathways of microorganisms and man often differ and these points of difference may 
be exploited in treating infectious diseases, as they can be used to kill disease-
causing microorganisms without harming the host (Hammond and Lambert, 1978). 
 
1.5.2 Spectra of activity 
Antibiotics are frequently grouped according to their spectra of activity, i.e. according 
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C. Antiprotozoal 
D. Antiviral agents 
E. Antitumour agents: justifiably classified also as antibiotics because the 
compounds were originally isolated on the basis of their antimicrobial activities 
(Okafor, 1987). 
 
Those antibiotics which are effective against a variety of pathogens are termed broad 
spectrum antibiotics (Hammond and Lambert, 1978). If effective mainly against 
Gram-positive or Gram-negative bacteria, they are narrow spectrum. If effective 
against a single organism or disease, they are referred to as limited spectrum (Todar, 
2009). 
 
1.5.3 Minimum inhibitory concentration (MIC) – Its significance 
As an index of antibiotic activity, microbiologists and clinicians use the minimum 
inhibitory concentration (MIC), defined as the lowest antibiotic concentration that will 
inhibit the growth of a specific organism (Okudoh, 2001). The MIC value is a 
characteristic of a particular antibiotic for a particular bacterial species under 
particular test conditions. In addition, within a given species, different strains may, 
within certain limits, be more or less sensitive to an antibiotic and therefore may have 
different MIC values (Lancini and Parenti, 1982). The MIC for an antibiotic against a 
given bacterium will differ according to whether it is determined in liquid or on solid 
medium, even when the two media are the same except for the agar (Lancini and 
Parenti, 1982). The MIC of many antibiotics is not affected by variation in the 
inoculum density in the range commonly used (103 – 106 bacteria/ ml-1) [Lancini and 
Parenti, 1982]. 
 
In the past, the method for MIC determination used test tubes or small bottles of 
growth broth containing a test concentration of antibiotics, into which an inoculum of 
microbes was added (Davidson and Parish, 1989). Currently, the tubes have been 
replaced by a semi-automated microtitre plate method (Lambert and Pearson, 2000; 
Rahman et al., 2004). To determine the MIC, a micro-titre plate (10 x 10 wells) 
containing graded doses of antibiotic, are inoculated with the test organism. After 
suitable incubation, growth will occur in those wells where the antibiotic concentration 
is below the inhibitory level and the culture will become turbid (cloudy) from the large 
number of microorganisms present. Growth will not occur when the concentration of 
the antibiotic is above the inhibitory level and the medium will remain clear (Okudoh, 
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2001). The MIC is the concentration of antibiotic present in the first “clear” well 




Fig. 1.11 Determination of minimum inhibitory concentration (MIC) on a microtitre plate: Each 
column contains a decreasing concentration gradient (H to B) of one antibiotic and all wells therein are 
inoculated with the test organism. Row A does not contain any antibiotic and serves as a growth control. 
The MIC of each antibiotic can be seen as the first row of each column showing no growth (clear broth).  
Columns 1 to 12 may contain different antibiotics. Source: Rahman et al., (2004). 
 
Where the turbidity of the test compound interferes with the test, indicators such as 
fluorescin diacetate, resazurin and p-iodotetrazolium can be used (Mann and 
Markham, 1998; Rahman et al., 2004). However, the principal problem encountered 
is that all MIC techniques currently used are semi-quantitative. Measuring the MIC of 
a substance by current methods is straightforward, whereas obtaining useful 
comparative information from the tests can be more difficult (Lambert and Pearson, 
2000). 
 
1.5.4 Minimal bactericidal concentration (MBC) 
A single antibiotic may be both bacteriostatic and bactericidal, depending on the 
concentration used (Lancini et al., 1995). Sometimes it is useful to determine the 
minimal bactericidal concentration (MBC). This is done in a similar manner to the 
MIC except that at the end of the incubation, an aliquot of liquid from each well/ bottle 
in which no growth can be seen, is diluted to remove the antibiotic and spread on the 
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surface of Petri plates containing an appropriate nutrient medium. These are 
incubated for 24h at an appropriate temperature. The MBC is the concentration of the 
antibiotic in the first clear well from which no colonies could be grown on the Petri 
plates. In practice, “no colonies” is defined as a 99.9% reduction in colony forming 
units (CFU) [Lancini and Parenti, 1982]. 
 
1.6 Mechanism of action of antibiotics – General overview 
The mechanism of action of an antibiotic is the biochemical event by which the 
growth of a sensitive microorganism is inhibited (Lancini and Lorenzetti, 1993). This 
is the result of the interference of the antibiotic with a molecule called the target 
molecule essential for cell growth. Target molecules are normally macromolecules 
such as DNA, RNA and enzymes, but are occasionally small metabolites such as 
substrates of enzymatic reactions or membrane components (Lancini and Lorenzetti, 
1993). 
 
The mechanism of action of antibiotics is well documented in the literature (Lancini 
and Parenti, 1982, Nagarajan, 1991, Allen, 2003, Walsh, C. 2003, Salyers and Whitt, 
2005, Todar, 2009). In this brief review, emphasis is laid on the bacterial cell wall 
since it is the first point of contact between the cell and all antibiotics and the review 
is limited to a few common examples of antibiotic classes. 
 
In order to comprehend how an antibiotic inhibits the growth of a bacterial cell, it is 
important to understand how the life of such an organism is constructed. The life of 
any organism requires provision of the following: precursors (building blocks), 
appropriate energy sources; and appropriate enzyme systems and components to 
carry out the contruction. It also involves the assembly of precursors into polymeric 
form and arrangement of the polymers into appropriate configurations and structures 
(Mayberry, 2004). 
 
Most antibiotic mechanisms operate by trying to stop one or two steps in the 
construction project. This can be achieved by inhibition of the following: production of 
coenzymes, production of precursors, assembly of enzymatically active structures 
and transport of structural components to appropriate sites. It also includes the 
inhibition of production of polymers and their rearrangement, and the disruption of the 
integrity of pre-existing structures (Mayberry, 2004). 
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Understanding the mechanism of action of an antibiotic molecule implies the 
identification of the target molecule(s), the inhibition site and the type of interaction 
(Lancini and Lorenzetti, 1993). For a large number of antibiotics, the target molecule 
is known. However, it is easier to identify the metabolic pathway that is blocked than 
the specific molecule involved. Therefore, we have antibiotics that either inhibits cell 
wall synthesis, DNA replication and transcription, protein synthesis or cell membrane 
functions (Lancini and Lorenzetti, 1993). 
 
1.6.1 Inhibition of bacterial cell wall (peptidoglycan) synthesis 
Fifty to seventy percent of the Gram-positive bacterial cell wall mass and to a lesser 
extent (10 – 15%) in Gram-negatives is composed of peptidoglycan (Fig 1.12). Its 
cross-linked structure provides a tough, fibrous fabric, giving strength and shape to 
the cell and enabling it to withstand a high internal osmotic pressure (Franklin and 
Snow, 1981). The bacterial cell wall is the point of inhibition by various classes of 
antibiotic e.g. penicillins, cephalosporins and vancomycin that affect either 
peptidoglycan synthesis or assembly of other components of the wall, e.g. teichoic 
acid (Franklin and Snow, 1981). 
 
1.6.1.1 Inhibition of precursor formation 
Two carbohydrate precursors (N-acetyl glucosamine and N-acetyl muramic acid) are 
required for peptidoglycan biosynthesis and are unique to prokaryotic cell walls 
(Walsh, C. 2003). Several amino acids, especially some of the „unnatural‟ “D-” 
configurations, are also required. The process also involves the carrier molecules 
(UDP, polyprenol) and an energy source ATP (adenosine triphosphate). The 
enzymes necessary to assemble these precursors into “building blocks” 
(transglycosylases), form linear glycan polymers which are crosslinked via peptide 
side chains to form a rigid 3-D peptidoglycan structure (transpeptidases) [Walsh, C. 
2003]. 
 
The steps in the formation of the carbohydrate precursors are shown in Figure 1.13. 
A typical carbohydrate reaction converts glucose to N-acetyl glucosamine – 1 – 
phosphate. Uridine triphosphate (UTP) is consumed and uridine diphosphate (UDP) 
is attached to form UDP – N-acetyl glucosamine (UDP-“G”).  Phosphenolpyruvate is 
added to the 3-oxy position of UDP-“G” via an ether linkage to form UDP – N-acetyl 
muramic acid (UDP-“M”). This provides a free carboxyl group which serves as an 
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“anchor” for subsequent additions of amino acids. The reaction is inhibited by 
fosfomycin, an epoxide analog of phosphenolpyruvate. Both UDP-”G” and UDP-”M” 
form the basis of the glycan portion of the peptidoglycan wall (Mayberry, 2004). 
 
 
Fig. 1.12 Structure of the bacterial cell wall. Source: Salyers and Whitt, (2005). 
 
The amino acid precursors are mainly glycine, L-alanine, D-glutamic acid, L-lysine 
and diaminopimelic acid (DAP). The structures of the amino acids found in 
peptidoglycan (murein) are shown in Figure 1.14. Glycine is used without any 
alteration in its structure as is L-alanine. However, L-alanine is also converted via a 
racemase to the “unnatural” D-alanine, which is then dimerized to D-alanyl-D-alanine. 
This D-alanyl-D-alanine dimer is important in the crosslinking of the peptide portion of 
the peptidoglycan wall. Production of D-alanine and its dimerization are both inhibited 
by D-cycloserine, a cyclic analog of D-alanine (Lancini et al., 1995; Walsh, C. 2003). 
 








Fig. 1.13 Formation of carbohydrate precursors, UDP-N-acetyl glucosamine and UDP-N-
acetyl muramic acid: (X) indicates the site of action of fosfomycin. Source: Mayberry, (2004). 
 
D-glutamic acid is formed by racemization of L-glutamic acid.  Currently there is no 
known inhibitor of this process. L-lysine is found in the walls of some Gram-positive 
bacteria while diaminopimelic acid (DAP) is found in Gram-negative and acid-fast 
bacteria (Ghuysen and Hakenbeck, 1994). 
 
1.6.1.2 Inhibition of glycan polymer synthesis 
In the assembly of the basic subunit of peptidoglycan, the wall precursors will have to 
be transported across a lipid membrane. This means that the carrier group on UDP-
”M”- pentapeptide must be changed from the water-soluble UDP to a C55 polyprenol-
P-P, forming lipid I (Fig. 1.15). A molecule of N-acetyl glucosamine (derived from 
UDP-”G”) is then linked via a glycosidic bond to lipid I, to form lipid II. Depending on 
the organism, a number of glycine molecules (activated as tRNA-glycine) are added 
to the free amine group of lysine (or DAP), forming a “Glycine bridge” of zero to 
several units (Mayberry, 2004). 
 
The next step in the biosynthesis of peptidoglycan is the extension of the glycan 
chain (transglycosylation). Lipid II molecules (with or without a glycine bridge) are 
transported through the cytoplasmic membrane to the site of wall extension. Then 
UDP-N-Acetyl Glucosamine 
UDP-“G” 
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transglycosylases add the carbohydrate dimer to the “growing” end of the glycan 






Fig. 1.14 Structures of amino acids found in peptidoglycan (murein). Production of D-alanine 
and its dimerization are both inhibited [sites (1) and (2)] by D-Cycloserine, a cyclic analog of 
D-alanine. Source: Mayberry, (2004). 
 
There are no current antibiotics available to inhibit the transglycolases, but the animal 
feed additive moenomycin is a model compound. The polyprenol-P-P must be 
dephosphorylated to polyprenol-P to be active in the cycle. This reaction is inhibited 
by bacitracin and related compounds (Mayberry, 2004). 
 
1.6.1.3 Inhibition of peptide crosslinking 
The final step in the biosynthesis of peptidogycan is the crosslinking reaction brought 
about by transpeptidation (Fig. 1.16). The newly formed glycan chain is a linear 
polymer and has no dimensional rigidity. Two and three-dimensional stability is then 
conferred by crosslinking of peptide chains from parallel glycan chains. 
Transpeptidases (also known as “penicillin-binding proteins”, PBPs) cleave the 
terminal D-Ala from D-Ala-D-Ala of one pentapeptide and use the energy to form a 
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peptide bond between the carboxyl group of the subterminal D-Ala and the free 
amine group of the glycine bridge, L-lysine, or diaminopimelate of a nearby 
pentapeptide (Mayberry, 2004). 
 
Fig. 1.15 Formation of the basic subunit of peptidoglycan and transglycosylation: (3) and (4) 




Fig. 1.16 Cross-linking of peptidoglycan (transpeptidation): Vancomycin and teichoplanin bind to 
D-Ala-D-Ala and prevent proper access by the PBPs; β-Lactam family (penicillins, cephalosporins, 
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A summary of the target sites in the bacterial cell wall biosynthetic pathway for selected 
antibiotics is shown in Table 1.5. 
 
Table 1.5 Antibiotics that inhibit bacterial cell wall biosynthesis. X and 1– 5 indicate the various 





Source: Mayberry, (2004). 
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1.6.2 Structural disorganization and functional inhibition of bacterial cell 
membranes – the polypeptide antibiotics 
The integrity of the cytoplasmic and, in Gram-negative bacteria, the outer membranes, 
is vital and compounds that disorganize the membranes rapidly kill the cells. Antibiotics 
that are active against the bacterial cytoplasmic membrane are the polypeptides 
[polymyxin B and E (colistin)], valinomycin, amphothericin B, etc. (Hammond and 
Lambert, 1978). Cell membranes have very similar constituents throughout the 
phylogenetic ladder from bacteria to mammalian cells. The only important difference is 
that there are no sterols in bacterial cell membranes, while zymosterol and ergosterol 
are present in the cell membranes of fungi and plants, and cholesterol in those of 
mammals. Some antibiotics in this group disorganize the super-molecular structure of 
the membrane, thus causing loss of cellular substance to the outside, while some act 
as carriers of specific ions (ionophores) and cause an abnormal accumulation of ions 
inside the cell (Lancini et al, 1995). The majority of inhibitors of cell-membrane 
functions are non-selective and consequently too toxic to be used systemically 
(Franklin and Snow, 1981; Axelsen, 2008). This discussion will be limited to the 
polypeptides since they are the most clinically successful in this group. 
 
Despite thousands of articles about hundreds of the polypeptide antibiotics over 
several decades, basic questions about their mechanism of action remain unanswered 
(Axelsen, 2008). Most investigators have concluded that they act solely by 
permeabilizing the bacterial cell membrane. Although strong evidence for another 
mechanism of action has not yet emerged, this conclusion may not represent the whole 
story because polypeptide antibiotics clearly have other significant effects on bacteria 
such as inhibition of ['4C] aminoacid incorporation into cell walls and the induced 
accumulation of uridine-nucleotide precursors of the cell wall under conditions in which 
incorporation of amino acids into protein is unaffected (Stone and Strominger, 1971).  
 
There are numerous polypeptide ‘antibiotics’ from bacterial, fungal, plant and animal 
(including human) sources which interact with and disrupt the structural and osmotic 
integrity of the outer and inner membranes of Gram-negative organisms. Some 
examples are polymyxin B, from Bacillus polymyxa, bacitracin from Bacillus 
licheniformis and vancomycin from Amycolatopsis orientalis (formerly Nocardia 
orientalis). Polymyxins bind to membrane phospholipids and thereby interfere with 
membrane function and are occasionally given for urinary tract infections caused by 
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Pseudomonas strains that are gentamicin, carbenicillin and tobramycin resistant. They 
act by competitively replacing Mg2+ and Ca2+ from negatively charged phosphate 




Fig.1.17 Disruption of a cell membrane by a polypeptide, polymyxin B: Source: Tritz, (2000)  
 
Bacitracin (Fig. 1.8B) prevents Gram-positive cell wall growth by inhibiting the release 
of the mucopeptide subunits of peptidoglycan from the lipid carrier molecule that 
carries the subunit to the outside of the membrane. Teichoic acid synthesis, which 
requires the same carrier, is also inhibited (Todar, 2009). The principal mode of action 
of bacitracin is to bind tightly to undecaprenol pyrophosphate (UPP) in the presence of 
a bound divalent metal cation, sequestering UPP and preventing its interaction with 
phosphatase (Drablos et al., 1999). This in turn prevents the return of undecaprenol 
monophosphate (UP) lipid carrier to the cycle, thereby inhibiting peptidoglycan and 
teichoic acid biosynthesis (Toscano & Storm, 1982). 
 
Vancomycin acts by inhibiting proper cell wall synthesis in Gram-positive bacteria. The 
mechanism inhibited, and various factors related to entering the outer membrane of 
Gram-negative organisms mean that vancomycin is not active against Gram-negative 
bacteria.  Specifically, vancomycin prevents incorporation of N-acetylmuramic acid 
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(NAM) - and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into 
the peptidoglycan matrix; which forms the major structural component of Gram-positive 
cell walls (Lilly, 1999). 
 
1.6.3 Inhibition of protein synthesis 
The inhibitors of protein synthesis mainly interfere with the functions of the 30S or 50S 
ribosomal subunit (Lancini and Parenti, 1982).  Aminoglycosides (e.g. streptomycin, 
kanamycin, paromomycin) interfere with decoding or translational accuracy of the 30S 
ribosomal subunit while spectinomycin disrupts translocation between A (aminoacyl), P 
(peptidyl) and E (exit) sites on ribosomes. Tetracyclines act by blocking proper binding 
of incoming aminoacyl-tRNA to the A site on the ribosome (Alekshun and Levy, 2007; 
Todar, 2009). They inhibit protein synthesis on isolated 70S or 80S (eucaryotic) 
ribosomes, and in both cases, their effect is on the small ribosomal subunit (Todar, 
2009). However, most bacteria possess an active transport system for tetracycline that 
will allow intracellular accumulation of the antibiotic at concentrations 50 times as great 
as that in the medium. This greatly enhances its antibacterial effectiveness and 
accounts for its specificity of action, since an effective concentration cannot be 
accumulated in animal cells. Thus a blood level of tetracycline which is harmless to 
animal tissues can halt protein synthesis in invading bacteria. Some newly discovered 
members of the tetracycline family (e.g. chelocardin) have been shown to act by 
inserting into the bacterial membrane, not by inhibiting protein synthesis (Todar, 2009). 
 
The 50s ribosome-binding antibiotics such as chloramphenicol, block the aminoacyl-
tRNA interaction with the peptidyltransferase center (A-site) in the 50S ribosome, 
inhibiting transpeptidation („connection‟) [Mayberry, 2004]. Macrolides (e.g., 
erythromycin, azithromycin, and clarythromycin) block the approach to the peptide exit 
tunnel, as well as blocking assembly of the 50s ribosome subunit. Ketolides (e.g., 
telithromycin) are modified macrolides and block the same sites. Linezolid is the first of 
a new class of synthetic antibiotics and it interacts with the peptidyltransferase center 
P-site and blocks the first peptide-bond forming step. Synercid is a naturally occuring 
mixture of compounds that synergistically block peptide translation in the 50s ribosome 
(Harms et al., 2004). Inhibitors of protein synthesis are bacteriostatic if they do not form 
irreversible bonds with some essential component of the synthetic system. If they do, 
they are bactericidal (Franklin and Snow, 1981). 
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1.6.4 Inhibition of nucleic acid synthesis 
Antibiotics with this mechanism of action include replication inhibitors and transcription 
inhibitors such as nalidixic acid and the quinolones (Okudoh, 2001). They act by 
inhibiting α- (or alpha-) subunit of DNA gyrases and topoisomerases. Novobiocin 
inhibits the β- (or beta-) subunit of DNA gyrases or topoisomerases. Rifampicin 
(rifamycin) inhibits RNA synthesis by RNA polymerase (Franklin and Snow, 1981). 
Most of the inhibitors of genetic material (nucleic acids) are used in cancer 
chemotherapy rather than as antimicrobial agents (Lancini et al, 1995). 
 
1.7 Industrial production of antibiotics  
The commercial production of antibiotics has been widespread since the pioneering 
efforts of Florey and Chain in 1938. Antibiotics are produced industrially by a process 
of fermentation where the source organism is grown in large fermenters (100 000 – 150 
000 litres or more) containing a liquid growth medium. Oxygen concentration, 
temperature, pH and nutrient levels must be optimal and are closely monitored and 
adjusted if necessary (Madigan and Martinko, 2005). 
 
As antibiotics are secondary metabolites the microbial population size must be 
controlled very carefully to ensure that maximum yield is obtained before the cells die. 
Once the process is complete, the antibiotic must be extracted and purified to a 
crystalline product. This is simpler to achieve if the antibiotic is soluble in an organic 
solvent and both the properties of the solvent and of the antibiotic are in equilibrium 
(Caco et al., 2008). The solubility of antibiotics in organic solvents plays a key role in 
the crystallization process which is a crucial step in the manufacture of many 
pharmaceuticals as pure products that are recovered easily through filtration (Gracin et 
al., 2002) Otherwise the antibiotic must first be removed by ion exchange, adsorption 
or chemical precipitation (Madigan and Martinko, 2005). 
 
1.7.1 Strains used for industrial production  
Microorganisms used in industrial fermentations are rarely identical to the wild type. In 
the antibiotic field, this is because species are often genetically modified to yield the 
maximum amounts of the substance. Mutation is often used and is encouraged by 
introducing mutagens such as UV radiation, X-rays or certain chemicals e.g. 
nitropyrenes, benzopyrene, ethylene oxide, ethionamide, etc. Ongoing selection of the 
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higher yielding strains over many generations can raise yields 20-fold or more 
(Madigan and Martinko, 2005). 
 
1.7.2 Antibiotics as secondary metabolites 
Products of industrial microorganisms are divided into two: primary and secondary 
metabolites from primary and secondary metabolism respectively. Primary metabolism 
is the interrelated series of enzyme-catalysed reactions which provide the cell with 
energy, synthetic intermediate products and macromolecules such as protein and 
nucleic acids. Products of primary metabolism are associated with cell growth and their 
maximum production occurs in the logarithmic phase of growth in a batch culture 
(Rose, 1979). 
 
In contrast to primary metabolism, secondary metabolism has no apparent function in 
the organism. The organism continues to exist if secondary metabolism is blocked and 
would die if primary metabolism were stopped. A summary of the major differences 
between primary and secondary metabolism is shown in Table 1.6. Antibiotics are the 
most successful products of secondary metabolism and will be the main focus of this 
review. 
 
1.7.2.1 Trophophase-idiophase relationships in the production of antibiotics 
The terms „trophophase‟ and „idiophase‟ were introduced by Bu‟Lock in 1965 to 
distinguish two phases of growth of organisms producing secondary metabolites. The 
trophophase (Greek, tropho = nutrient) is the feeding phase of the growth curve, while 
the idiophase (Greek, idio = peculiar) is the antibiotic production phase. The 
trophophase occurs at the logarithmic phase while idiophase occurs at the end of the 
logarithmic and in the stationary phase of the growth curve. The name „idiolites‟ has 
been suggested for secondary metabolites to distinguish them from primary 
metabolites (Demain, 1974). 
 
Relationship between antibiotic production and sporulation has been reported (Martin 
and Demain, 1978). An example is in the production of peptide antibiotics by Bacillus 
spp. Both spore formation and antibiotic production were suppressed by glucose; non-
spore forming mutants of bacilli also did not produce antibiotics, while reversion to 
spore formation was accompanied by antibiotic production (Demain, 1974).  
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Table 1.6 Major differencies between primary and secondary metabolism 
Primary metabolism Secondary metabolism 
Interrelated series of enzyme-catalysed 
reactions 
Specific enzymatic reactions 
Same for all species Species specific 
Metabolites not excreted into medium Metabolites excreted into medium 
Metabolites not overproduced Metabolites often overproduced 
Products rarely accumulates in medium Products accumulates in substantial quantities 
Non repression of product synthesis Frequent feedback inhibition 
Product formation parallel with growth Late formation of products 
Products essential for growth and reproduction Products has no apparent function in the 
organism 
Product completely created from growth 
substraes 
Product initially created from primary 
metabolites and later from growth substrates 
Unrelated products Family of closely related products 
Provide cell with energy Means of cell protection from adverse 
environment 
Source: Adapted from Madison and Martinko, (2005). 
 
Many roles have been assigned to antibiotics in spore-formers but the most clearly 
demonstrated has been the essential nature of gramicidin in sporulation of Bacillus 
spp. The absence of the antibiotic leads to partial deficiencies in the formation of 
enzymes involved in spore formation, resulting in abnormally heat-sensitive spores 
(Okafor, 1982). The antibiotic, therefore, suppresses the vegetative genes allowing 
proper development of the spores. It appears, therefore, that the production of 
secondary metabolites is necessary to regulate some morphological changes in the 
organism. It could of course be that some external mechanism, nutritional or otherwise, 
triggers off antibiotic formation as well as the process of spore formation (Okafor, 
1982). 
 
1.7.2.2 Control of antibiotic production 
Most organisms are able to decide when to manufacture and secrete certain enzymes 
to enable it to utilize materials in the environment and also to stop the manufacture of 
certain compounds if they are supplied to it. These sensing mechanisms for the 
switching on and off of synthetic mechanism enable the organism to avoid the over-
production of any particular compound (Okafor, 1982).  
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The regulatory control of the organism against over-production of secondary 
metabolites is controlled at three levels: (i) the regulation of enzymes (ii) permeability of 
the organism and (iii) the genetic level. In this review, the regulation of enzymes as it 
affects antibiotics control will be discussed.  
 
Enzyme repression 
Often the enzymes catalyzing the synthesis of antibiotics are not synthesized if a 
particular substance is present in the medium. A good example is in penicillin 
production where the antibiotic is not produced in a glucose-containing medium until 
after the exhaustion of the glucose, and when the idiophase sets in. Indeed, the 
„glucose effect‟ as it is known is common to a large number of secondary metabolites 
(Okafor, 1982). It was found that the glucose (substrate) level does not repress the 
penicillin production but it represses the synthesis of the enzymes necessary for the 
formation of the antibiotic (Okafor, 1982). 
 
Enzyme induction 
Some enzymes are produced by microorganisms only when the substrate on which 
they act is available in the medium. Examples include enzyme induction by methionine 
in the synthesis of cephalosporin C by Cephalosporium ocremonium and also by 
tryptophan in ergot alkaloid fermentation (Drew and Demain, 1977). 
 
Feedback inhibition 
A major mechanism for the regulation of enzymes involves the phenomenon of 
feedback inhibition (Madigan and Martinko, 2005). In feedback inhibition, the end 
product of a biosynthetic pathway inhibits the activity of the first enzyme in this 
pathway. Thus, as the end product builds up, its further synthesis is inhibited. If the end 
product is used up, however, synthesis can resume (Fig. 1.18).  
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The above inhibition is made possible by allosteric enzymes which has two combining 
sites, the active site, where the substrate binds, and the allosteric site, where the 
inhibitor (effector) binds reversibly. When the effector combines with the allosteric site, 
the conformation of the enzyme is altered so that the substrate can no longer bind 
(Madigan and Martinko, 2005). 
 
                           
Fig. 1.18 Feedback inhibition: The activity of the first enzyme is controlled by the end product, thus 
controlling production of end product. 
 
1.7.3 Optimization of antibiotic yield – from laboratory to industry 
Most antibiotic production in the laboratory is carried out at the shake flask level and 
lacks a clear understanding of the production process requirements in industry, offering 
poor prospects for successful scale-up. There is a need for early data collation on 
media and physical optima differences between the trophophase (growth phase) and 
idiophase (production phase) to allow implementation of novel fermentation protocols 
(Marwick et. al. 1999). Cognisance of factors described below is necessary to achieve 
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1.7.3.1 Manipulation of media components 
Carbon 
The choice of carbon source greatly influences antibiotic production (Spizek and Tichy, 
1995). A quickly metabolized substrate such as glucose may often achieve maximum 
cell growth rates but tends to inhibit the production of many secondary metabolites 
through catabolite repression. The reason is that intermediate products generated from 
the rapid catabolism of glucose interfere with the enzymes participating in the 
secondary metabolism process (Gallo and Katz, 1972). Fast growing cells generally 
have secondary metabolism switched off until their growth rate slows, via feedback 
inhibition. This can lead to a fully biphasic fermentation profile, with no production 
during growth, only during the stationary phase (Liao et. al. 1995). Galactose, which is 
a slowly utilized substrate, can improve antibiotic yields especially in fungi. 
Nevertheless, the separation of trophophases and idiophases is not well-defined. 
Production of bacitracin by Bacillus licheniformis can be observed during the growth 
phase, when a slow growth medium is used. Glycerol was found to increase the total 
yield of manamycin by a Streptomyces species when it was fed during the production 
phase (Kaiser et al., 1994). 
 
Nitrogen 
The nitrogen source tends to regulate, secondary metabolism and high nitrogen levels 
repress idiophase production of many antibiotics (Doull and Vining, 1990; Spizek and 
Tichy, 1995). However, Zhang et al., (1996) found low ammonium levels to stimulate an 
antibiotic produced by Streptomyces griseofuscus. The use of unstable amino acids as 
a nitrogen source can inhibit good synthesis of secondary metabolites (Martin and 
Demain, 1980). The effect may be due to a specific amino acid interacting with the 
regulation of secondary metabolic pathways. Therefore, it is necessary to optimize the 
nitrogen type and concentration at different stages of antibiotic production. 
 
Phosphate 
Phosphate, although essential for growth, can at below or above optimal 
concentrations suppress secondary metabolism (Spizek and Tichy, 1995). Interestingly, 
the level of adenosine triphosphate (ATP) has been observed to decrease significantly 
before secondary metabolism begins. This was attributed to a rise in phosphatase 
activity after the cessation of growth (Marwick et al., 1999). 
 




The effect of specific metal ions on Burkholderia glume, with regard to secondary 
metabolite production, was investigated by Yamaski et al., (1998), who concluded that 
certain metal ions such as Zn2+, K+ and Fe3+ gave optimum yields. If MgCl2 was 
replaced by MgSO4, no production occurred. Zinc sulphate was found to increase 
phenazine production by P. fluorescens (Slininger and Jackson, 1992). Similarly, KNO3 
or FeCl3 increased phytotoxin production by P. syringae (Palmer and Bender, 1993). 
The above results have interesting implications in fermentation for the control of 
antibiotic production. 
 
1.7.3.2 Alteration of physical parameters 
Temperature 
Temperature is a regulatory factor in secondary metabolism of Streptomyces 
thermoviolaceus (James et al., 1991) and mycotoxin production by Aspergillus species 
increased when temperature was reduced from its natural level (Tepsic et al., 1997). A 
Lactobacillus sp. yielded more exopolysaccharide with a temperature shift from 37oC to 
25oC at the beginning of the exponential phase (Gamar et al., 1998). Therefore, 
temperature shifts or cycles may be necessary during fermentations for antibiotic 
production (Marwick et al., 1999). 
 
PH 
The pH level of a growth medium has a marked effect on secondary metabolite 
production, with synthesis falling rapidly on either side of the optimal level. This was the 
case for violacin production from the marine bacterium Alteromonas leuteoviolacea, 
which ceased at pH 9 after an optimum had been reached at pH 7 (McCarthy et al., 




Oxygen transfer is a major limiting factor in antibiotic production. An increase in partial 
pressure of oxygen was found to induce new metabolite synthesis by Streptomyces 
parvulus (Kaiser et al., 1994). The oxygen transfer from sparged air to the bacterial cell 
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is partially dependent on medium composition, a viscous medium being harder to 
oxygenate than a non-viscous one (Švitel and Šturdik, 1995). 
 
Salinity 
Some bacteria living in a marine environment require salt for growth (Kogure, 1998). 
However, the effect of salt on antibiotic production has not been extensively 
researched. Salinity was found by Okami et al. (1976) to effect the production of 
aplasmomycin by a marine Streptomyces sp. High salt content may cause problems 
with bioreactor corrosion, and may also inhibit the dissolution of sparged oxygen into a 
water-based medium (Garcia and Gordon, 1992). 
 
Pressure 
Pressure may act as a stressor to increase antibiotic production via Le Chatelier‟s 
principle, if a negative volume change in reactants to products is favoured (Wright et 
al., 1999). 
 
1.7.3.3 Regulatory factors 
Induction 
Inducing antibiotic production during the growth phase, thereby overriding feedback 
inhibition can increase antibiotic yields. This has already been achieved in 
Streptomyces culture, where virginiae butanolides (an auto regulator for antibiotic 
synthesis) was added after 8 hours, resulting in a doubling of virginomycin production 
(Young et al., 1995). Also, antibiotic production can be induced by antagonizing the 
bacterial cells into defending themselves against a perceived threat. For example, 
Fredrickson and Stephanopoulus (1981) stated that microbes competing for a single 
nutrient would try to eliminate one another via toxic warfare. In fact, a new method has 
been developed to enhance antibiotic production by marine bacteria, namely the use of 
terrestrial bacteria as antagonists (Burgess et al., 1999). 
 
Induction does not necessarily have to involve microbial products; thus the antibiotic 
production of a marine Bacillus was found to be dependent on the addition of an amino 
acid analogue, selenomethionine (Imada et al., 1998). Such control of secondary 
metabolism so as to override normal primary metabolic repression can be very useful in 
intensified production of antibiotics (Marwick et al., 1999). 
 




Auto-inhibition of antibiotic-producing microbes is well documented (Anderson et al., 
1974; Lemos et al., 1991). The use of a continuous or semi-continuous fermentation 
protocol allows extraction of any inhibitory compounds from the medium, ensuring no 
repression of antibiotic production rates (Marwick et al., 1999). 
 
Genetics  
Genetic manipulation of antibiotic-producing microbes to increase yield is well 
established (Matsunaga and Takeyama, 1995; Lloyd et al., 1997; Hosoya et al., 1998). 
Copies of genes encoding for enzymes involved in antibiotic production can be inserted 
into a cell, via vectors such as plasmids. This process is closely linked with retesting of 
antibiotic production and effectiveness (Madigan and Martinko, 2005)  
 
1.7.4 Fermentation process development 
Optimization of product yield in the laboratory is followed by process scale-up; first to 
pilot scale of 10 – 100 L and finally to industrial scale of 1000 to 100 000 L, or more, 
depending upon the specific process. However, during the scale-up process, 
decreased product yields are often experienced because the conditions in large scale 
fermenters are not identical to those experienced in the smaller-scale laboratory or pilot 
plant systems (Waites et al, 2001). The essential components of fermentors used in 
antibiotic production are shown in Figure 1.19. 
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Fig. 1.19 The essential components of a completely stirred tank fermenter used for penicillin 
production. Source: Cowan, (2009). 
 
Once a microorganism has been selected as a producer organism for a particular 
antibiotic, media formulation and an examination of operating systems (batch, fed-
batch, continuous, etc. (Fig. 1.20) are researched along with selection of the most 
suitable type of fermentation system (stirred tank, airlift, packed bed, solid state, hollow 
fibre, etc.). Other factors that are considered include fermenter configuration and 
control of pH, dissolved oxygen, foam and temperature (Cowan, 2009). 
 
A stirred batch fermenter is a closed system where all nutrients are present at the start 
of the fermentation in a fixed volume, whereas in a fed-batch fermenter fresh medium is 
introduced throughout the fermentation and the volume of the batch increases with 
time. Continuous culture is where fresh medium is fed constantly into the vessel and 
spent medium and cells are removed at the same rate (fixed volume). In all systems, 
pH, temperature, aeration, etc., are monitored and adjusted (Cowan, 2009). 
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There are obvious advantages and disadvantages in each of the operating systems.  
The batch system is the simplest fermenter operation. Sterilisation can be performed in 
the reactor and all nutrients can be added before inoculation. However, biomass 
production is limited by carbon/nitrogen (C/N) load and production of toxic waste 
products. The cells are harvested when biomass levels or product levels start to decline 
(Cowan, 2009).  
  
 
Stirred batch fermenter Fed-batch fermenter  Continuous fermenter 
 
Fig. 1.20 Design of fermentation systems used in antibiotic production. Source; Cowan, (2009). 
 
In the fed-batch system the initial medium concentration is relatively low (no inhibition 
of culture growth) and the medium constituents (concentrated C and/or N feeds) are 
added continuously or in increments. This controlled feed results in higher biomass and 
product yields. However, fermentation is still limited by accumulation of toxic end 
products (Cowan, 2009). 
 
The continuous fermenter has an input rate that is equal to output rate (total operating 
volume is constant) and the flow rate can be selected to give steady state growth 
(growth rate is equal to dilution rate) of the microbial cells. If the dilution rate is greater 
than, less than or equal to the growth rate the culture either washes out, overgrows or 
remains stable respectively. The product is harvested from the outflow stream and this 
system can be operated continuously for weeks or months (Cowan, 2009). 
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1.8 Bacterial resistance to antibiotics – General overview 
Antibiotic resistance is the ability of a microorganism to withstand the effects of 
antibiotics. This resistance evolves via natural selection acting upon random mutation, 
but it can also be engineered by applying an evolutionary stress on a population (Fig. 
1.21). If a bacterium carries several resistance genes, it is called multiresistant or, 
informally, a superbug. The different resistance genes are linked to each other on 
segments of DNA able to move efficiently from one bacterial cell to another by a 




Fig. 1.21 Scheme of evolution of resistant strains in a bacterial population, Source: Wikipedia, 
(2009). 
 
Horizontal gene transfer can occur by three basic mechanisms: transformation (the 
release of free DNA from one bacterial cell to be actively taken up by another); 
transduction (transfer of DNA via the use of bacterial viruses [phages] as “vectors”); 
and conjugation (the movement of DNA from one cell to another via cell-to-cell 
contact). Conjugation phenomena frequently involve mobile plasmids or conjugative 
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transposons, which encode their ability to move copies of themselves from one 
bacterial cell to another and are widespread in the bacterial world (Clewell and Francia, 
2004; Lawley et al., 2004). Such transferable elements have been the subject of much 
investigation (Clewell, 1993; Funnell and Phillips, 2004). 
 
Staphylococcus aureus is arguably the most troublesome of all the human pathogens 
(Kassem et al., 2007) and has resisted the effects of almost all clinically used 
antibiotics (Chopra et al., 1997; Weigel, 2003; Tenover and McDonald, 2005) and 
consequently will merit a brief discussion here. 
 
1.8.1 Methicillin resistant Staphylococcus aureus (MRSA) 
Staphylococcus aureus is found on mucous membranes and the skin of around a third 
of the animal population and it is extremely adaptable to antibiotic pressure. It was the 
first bacterium in which penicillin resistance was found in 1947, just four years after the 
drug started being mass produced. Methicillin was then the antibiotic of choice, hence 
the name, methicillin-resistant Staph aureus (MRSA). However, methicillin has since 
then been replaced by oxacillin due to significant kidney toxicity (Kassem et al., 2007).  
 
Methicillin-resistant Staphylococcus aureus was first detected in Britain in 1961 and is 
now quite common in hospitals around the world. Half of all S. aureus infections in the 
United States are resistant to penicillin, methicillin, tetracycline and erythromycin. This 
left vancomycin as the only effective agent available at that time (Barrett, 2005). 
However, strains with intermediate (4 – 8 μg/ml) levels of resistance, termed GISA 
(Glycopeptide intermediate S. aureus) or VISA (Vancomycin intermediate S. aureus), 
began appearing in the late 1990s (firstly in Japan in 1996). In 2002, the first strain with 
complete resistance to vancomycin, VRSA (Vancomycin resistant S. aureus) appeared 
in the US (Tenover and McDonald, 2005).  
 
A new class of antibiotics, oxazolidinones, became available in the 1990s to treat 
MRSA. Linezolid is comparable to vancomycin in effectiveness against MRSA, but 
resistance to linezolid as well as daptomycin has already been described (Tsiodras et 
al., 2001; Meka and Gold, 2004; Mangili et al., 2005). 
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Community-acquired MRSA (CA-MRSA) has emerged as an epidemic that is 
responsible for rapidly progressive, fatal diseases including nectrotizing pneumonia, 
severe sepsis in many hospitals and these infections now appear to be endemic in 
many urban regions around the world. This scenerio can be likened to the emergence 
of high-level vancomycin resistance in Staphylococcus aureus (Weigel, 2003) and the 
growing presence of multiple drug-resistant strains of Mycobacterium tuberculosis 
(Wright, 2006).  
 
1.8.2 Mechanism of resistance – General overview 
This review focuses mainly on the three major strategies used by bacteria for 
resistance to most of the important antibiotics in use today. Firstly, they inactivate the 
antibiotics by producing specific-proteins that chemically modify the antibiotic to a form 
that no longer interferes with the bacterial function (Salyers and Whitt, 2005). A second 
strategy is to reduce the intracellular antibiotic concentration by inserting a protein 
pump (called efflux pumps) into the cytoplasmic membrane. This bacterial protein 
pump can eject the antibiotic from the cytoplasm as rapidly as it enters the cell. A third 
resistance strategy is to chemically modify or mutate the target of the antibiotic so that 
the antibiotic can no longer bind to it. This strategy can be very dangerous to the 
bacteria because the mutation may disrupt the processes essential for bacterial 
survival (Salyers and Whitt, 2005). 
 
The strategies used by bacteria to resist the action of β-lactams, polypetides and 
aminoglycosides will be discussed. The following discussion will also look at three other 
clinically important antibiotic groups namely, the tetracyclines, macrolides and 
rifampicin.  
 
The first mechanism of bacterial resistance to penicillin to be described involved the 
enzyme β-lactamase. This enzyme cleaves the β-lactam ring of penicillin (Fig. 1.4), 
rendering the antibiotic inactive (Salyers and Whitt, 2005, Hubschwerlen, 2007). 
 
Βeta-lactamases seem to have evolved from the proteins that catalyze the cross-linking 
of peptidoglycan, the proteins that are the target of penicillin. When penicillin binds one 
of the proteins, the protein mistakes penicillin for the two alanines found at the end of 
the peptide that normally participate in the cross-linking reaction. The cross-linking 
 
     
54 
enzyme can start but not complete the hydrolysis of the β-lactam ring. The partially 
hydrolyzed antibiotic is then trapped in the active site of the enzyme which would 
normally cease to function. However, the enzyme has evolved to complete the 
reaction, hence releasing a penicillin molecule with a broken β-lactam ring (Salyers and 
Whitt, 2005). 
 
To combat bacterial β-lactamases scientists have developed modified forms of 
penicillin such as carbapenem (Fig. 1.4) by surrounding the β-lactam ring with other 
chemical groups. These new antibiotics are called β-lactamase-resistant β-lactams 
(BLRBLs). However, β-Lactamases themselves mutate so that the new drugs are no 
longer effective (Hubschwerlen, 2007). 
 
Another attempt by scientists to deal with β-lactamases was to develop an antibiotic 
preparation that contains both the antibiotic and an inhibitor of β-lactamase e.g. 
augmentin which contains a compound (clavulanic acid) that inhibits the bacterial 
enzyme so that it can no longer destroy amoxicillin, a member of the penicillin family 
(Salyers and Whitt, 2005). 
 
Vancomycin resistance emerged from a strain of Staphylococcus aureus called 
vancomycin-resistant S. aureus (VRSA) that started out being resistant to many 
antibiotics, including β-lactams. Vancomycin resistance is regarded by many scientists 
as the last frontier in the battle between bacteria and humans (Dale-Skinner and 
Bonev, 2008). Vancomycin was originally thought to be the ultimate resistance-proof 
antibiotic because becoming resistant to it would require bacteria to change their cross-
link peptide structure, a change that might be lethal to the bacterium (Salyers and 
Whitt, 2005). However, resistance to vancomycin actually involves several genes 
encoding several proteins that comprise a pathway for changing the peptidoglycan 
cross-linking peptides into a form that no longer binds vancomycin but will still be cross-
linked by bacterial enzymes. There is also a gene that encodes an enzyme that 
degrades the original terminal D-alanine-D-alanine part of the cross-linking peptide 
(Fig. 1.22) [Salyers and Whitt, 2005]. 
 
Resistance to polypeptide antibiotics is common, and different polypeptides tend to 
have different patterns of resistance or susceptibility among bacteria. Resistance to 
any one polypeptide often varies widely among closely related bacterial species, and 
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can even vary among different strains of the same species (Axelsen, 2008). In any 
case, bacteria do not develop secondary resistance when cultivated in sub-inhibitory 
concentrations of polypeptide antibiotics (e.g. Bacitracin), as is usually the case with 
antibiotics in other classes (Howard, 2008). This “resistance to acquired resistance” 
has drawn considerable attention among investigators seeking new antibiotics for use 
against the growing menace of pathogens with multidrug resistance (Axelsen, 2008). 
 
 
Fig. 1.22 The mechanism of vancomycin resistance. Two enzymes in the resistance pathway 
replace the D-alanine-D-alanine with D-alanine-D-lactate, which does not bind vancomycin. One 
enzyme links D-alanine to D-lactate. A second one converts pyruvate, an intermediate in 
glycolysis, to D-lactate. A third enzyme hydrolyses any normal D-alanine-D-alanine peptides 
that might form and be bound by vancomycin. The cross-linking enzymes of the cell seem to be 
able to handle the D-alanine – D-alanine to D-alanine-D-lactate change and thus do not need to 
be modified. The encircled V represents vancomycin, which is no longer able to bind. (Source: 
Salyers and Whitt, 2005). 
 
One way bacteria can become resistant to aminoglycosides e.g. streptomycin is to 
mutate the ribosomal protein that provides the binding site for the antibiotic. The 
antibiotic will no longer bind to the ribosome and thus will no longer inhibit the growth of 
the bacteria. The fact that different aminoglycosides bind to different ribosomal proteins 
means that mutation of one ribosomal protein does not confer resistance to all 
members of the antibiotic family, yet there are strains of bacteria that are resistant to 
many aminoglycosides (Davies and Wright, 1997). Many of these multiresistant strains 
have acquired an enzyme that modifies aminoglycosides by covalently attaching a 
chemical group (phosphoryl, acetyl, adenyl) to the antibiotic (Fig. 1.23). Modification of 
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the antibiotic prevents it from binding to the ribosome and thus eliminates its ability to 
stop protein synthesis (Salyers and Whitt, 2005). 
  
Fig. 1.23 Modification of aminoglycosides by attachment of chemical groups such as acetyl (A), 
adenyl (B), and phosphoryl (C). Source: Salyers and Whitt, (2005). 
 
Bacteria can also become resistant to aminoglycosides by failing to take them up 
(Davies and Wright, 1997). Aminoglycosides are charged molecules that do not diffuse 
readily through the cytoplasmic membrane of a bacterium. Thus, they can enter the 
bacterial cell only if they are actively transported through the membrane. This type of 
resistance is not fully understood because scientists still have to identify the proteins 
that transport aminoglycosides into the bacterial cytoplasm (Davies and Wright, 1997). 
 
In contrast to the aminoglycoside antibiotics, tetracyclines diffuse readily through 
bacterial membranes, so that cells cannot become resistant to it by failing to take up 
the antibiotic. However, three mechanisms of resistance to tetracycline have been 
elucidated (Salyers and Whitt, 2005). The first mechanism to be discovered was called 
antibiotic efflux in which a protein located in the bacterial cytoplasmic membrane 
actively pumps tetracycline out of the cell (Levy, 1992; Salyers and Whitt, 2005) [Fig. 
1.24]. A similar mechanism has also been implicated in resistance of cancer cells to 
antitumour drugs (Salyers and Whitt, 2005). 
 
A second type of resistance is mediated by a bacterial protein that protects the 
ribosome (Fig. 1.25) by modifying it so that it no longer binds tetracycline but is still 
able to synthesize proteins (ribosome protection-type tetracycline resistance (RPTS). In 
this case, tetracycline accumulation within the cell is similar to that in a sensitive cell, 
but the ribosome is protected (hatching) [Fig. 1.25], so that tetracycline no longer binds 






Fig. 1.24 Mechanisms of bacterial resistance to tetracycline: A, Tetracycline (black squares) is 
taken up by a transporter (open ellipse) causing the intracellular concentration to become higher 
than the extracellular concentration which allows tetracycline to bind to the ribosomes in 
sensitive cells thereby stopping protein synthesis. B, cytoplasmic membrane protein (open 
triangles) pumps tetracycline out of the cell as fast as the transporter takes it up resulting in the  
intracellular concentration remaining too low for effective binding to ribosomes. Source: Salyers 
and Whitt, (2005). 
 
A third type of resistance is found only in strains of Bacteroides species that normally 
live in the human intestinal tract. This form of resistance is mediated by an enzyme that 
chemically modifies tetracycline, rendering it inactive (Salyers and Whitt, 2005).  
 
The macrolides (e.g. clarithromycin and erythromycin) are useful as alternative 
treatments to patients who are allergic to penicillin (Neu, 1991) and are normally used 
to treat respiratory and wound infections. More recently clarithromycin has been 








Erythromycin acts by binding to the 50S subunit of the bacterial ribosome and 
preventing the elongation of bacterial proteins. This type of mechanism is shared by 
two other classes of antibiotics, lincosamides and streptogramins that do not have the 
same structure. They also share the same mechanism of resistance. This is because, 
the 26S rRNA molecule, a large subunit rRNA molecule, forms the centre of the binding 
site of all three classes of antibiotic. Thus, a bacterial enzyme that methylates a key 
residue on this rRNA molecule simultaneously confers resistance to all three classes of 
antibiotics by reducing their binding to the ribosome (Salyers and Whitt, 2005). 
 
Resistance to rifampicin occurs readily from mutations in the β-subunit of RNA 
polymerase that prevents rifampicin from binding to it. Such mutations occur very 
readily, which is one reason why rifampicin is used mostly in combination with other 
tuberculosis (TB) antibiotics (cocktail). Some of the antibiotics included in the cocktail 
are fluoroquinolones, streptomycin, isoniazid, ethambutol, and pyrazinamide (Salyers 
and Whitt, 2005). Most TB patients do not comply very well with a drug regimen that 
forces them to take several antibiotics daily or 2 to 3 times a week for more than 6 
months. In the case of HIV patients, the TB treatment takes up to a year or even more. 
This problem led to the introduction of DOTS (directly observed therapy short course) 
in the United States. It compels TB patients to come regularly to a clinic or to have 
health workers visit them in their homes to make sure that the full course is taken. The 
DOTS programme was highly effective and helped to reduce the risk of Mycobacterium 
resistance to TB drugs in the US (Salyers and Whitt, 2005). 
 
1.8.3 Resistance and chemotherapy 
There are many reasons that lead to treatment failure with antibiotics, some of which 
have been wrongly credited to microbial resistance (Salyers and Whitt, 2005): (1) 
misdiagnosis of infection; although antibiotics will have no effect if the causative agent 
of a disease is a virus or a fungus, some physicians still prescribe them; (2) use of an 
antibiotic that has the wrong pharmacokinetic properties i.e. where an antibiotic fails to 
get to where it is needed e.g. an antibiotic that does not penetrate the blood-brain 
barrier will not help a meningitis patient that has bacteria in the cerebrospinal fluid; (3) 
lack of essential information on the best type of antibiotics to use in treating some 
disease conditions e.g. the presence of dead tissues in abscesses can inhibit the 




the full course of a prescribed antibiotic and this results in treatment failure. In order to 
work, an antibiotic must interact with the appropriate target, in the appropriate location 
in the cell, at the appropriate concentration – any change might lead to development of 
resistance (Salyers and Whitt, 2005; Todar, 2009). 
 
1.9 The future of antibiotic research – General overview 
There are few new antibiotics in the pipeline today (Mian and Davis, 2010). The 
reasons may include starvation at the front of the pipeline due to inadequate sources of 
suitable compounds to screen coupled with poorly validated discovery methodologies. 
A successful antibiotic discovery approach in the past, based upon whole cell antibiotic 
screening of natural products from actinomycetes and fungi, eventually suffered from 
constipation in the middle of the pipeline due to rediscovery of known compounds, 
even though low throughput methodology was employed at the front end. The current 
lack of productivity may be attributed to the poor choice of strategies to address the 
discovery of new antibiotics (Baltz, 2006). Approaches to accelerate antibiotic 
discovery from microorganisms as recommended by Baltz (2006) are summarized in 
Table 1.7. 
 
Table 1.7 Approaches to accelerate antibiotic discovery from microorganisms  
High-throughput whole cell screening of terrestrial microorganisms 
        Global soil sampling 
        Pooling of soils and extraction of spores 
        Miniaturized fermentations starting with spores 
        Screening organism resistant to common antibiotics 
        Improved throughput with automation 
Enrichments and selections for uncommon terrestrial and marine microbes 
        Antibiotics and taxon selective media 
        Untapped random and exotic soils 
        Untapped marine sediments 
Genome mining 
        Sequencing multiple common microbes 
        Sequencing rare and slow growing microbes 
        Expression of new pathways in robust bacterial hosts 
Combinatorial biosynthesis 
        NRPS pathways 
        PKS pathways 
        Glycosylations and other modifications 





However, recent applications of high throughput in vitro screening of individual 
antibacterial targets to identify lead compounds from combinatorial chemical libraries, 
traditional chemical libraries, and partially purified natural product extracts has not 
produced any significant clinical candidates. The solution to the current dilemma may 
be to return to natural product whole cell screening. For this approach to work in the 
current millennium, the process needs to be miniaturized to increase the throughput by 
orders of magnitude over traditional screening, and the rediscovery of known antibiotics 
needs to be minimized by methods that can be readily monitored and improved over 
time (Baltz, 2006). 
 
It is suggested that an improved understanding of the biological roles of low molecular 
weight compounds in nature will lead to the discovery of an inexhaustible supply of 
novel therapeutic agents in the next decade. To support this objective, a functional 
marriage of biochemistry, genomics, genetics, microbiology, and modern natural 





MATERIALS AND METHODS 
2.1 Introduction 






































Fig. 2.1 Flowchart indicating sequential steps in the antibiotic recovery, purification and bioassay 
procedures used. 
 
2.2 Sources and geographical distribution of samples 
Soil samples (± 10 g) were collected at depths of 0–5 cm below the surface from 
various sites in the KwaZulu-Natal Midlands (Table 3.1, Chapter 3). The samples were 





2.3 Sample preparation 
Each sample was prepared, first, by vigorous hand-shaking in an autoclaved (121oC, 
15 min) 1-litre beaker. All stones and large debris were subsequently removed 
aseptically. An approximately 1 g portion of each sample was suspended in 10 ml 
sterile distilled water from which three dilutions (10–2 to 10–4) were prepared with 
vigorous shaking at each step. Each dilution was divided into four equal aliquots, which 
were subjected to different treatments before plating on appropriate isolation media. 
Some samples were heat-pretreated in a waterbath at 70°C for 10 minutes (Cross, 
1981) and incorporated together with selective antibiotics into the isolation media. In 
others, there was no heat-pretreatment but a selective antibiotic was added to the 
media. The remaining samples had neither heat-pretreatment nor antibiotic 
incorporation into the media. 
 
2.4 Media 
2.4.1 Isolation media 
Distilled water was used for all media preparation. The following selective media were 
used: Czapek‟s medium (Cross, 1981) supplemented with 25 µg/ml novobiocin and 50 
µg/ml cycloheximide; Kosmachev‟s medium (Kosmachev, 1960); M3 Agar (Rowbotham 
and Cross, 1977),  MGA medium (Nonomura and Ohara, 1971)  modified by omitting 
soil extract and vitamin solution and made more selective by the addition of 10 µg/ml 
polymyxin B and 12 µg/ml oxytetracycline; Czapek‟s agar (Higgins and Lechevalier, 
1969)   modified by addition of 50 µg/ml cycloheximide and 4 µg/ml thiamine-HCl; 
Winogradsky‟s nitrite medium (Winogradsky, 1949)  and Yeast extract-malt extract agar 
[International Streptomyces Project (ISP) medium 2 (Pridham et al., 1957)]  modified by 
addition of gentamicin to the autoclaved and cooled medium to give a final 
concentration of 50 µg/ml. The cycloheximide was added to inhibit development of 
invasive fungi. The antibiotics used were chosen on the basis of good results obtained 
by previous investigators attempting the selective isolation of rare actinomycetes 
(Williams and Davies, 1965; Hayakawa and Nonomura, 1984; Ntuli, 1994). All plates 






2.4.2 Primary screening media 
The media used in primary screening for antibiotic-producing isolates were Iso-
sensitest agar (Oxoid) or Mueller-Hinton (MH) agar (Oxoid). 
  
2.4.3 Antibiotic production media 
The media used for antibiotic production were Nutrient broth (NB) [meat extract 1 g/l, 
yeast extract 2 g/l, peptone 5 g/l and sodium chloride 8 g/l, pH 7.1 after sterilization] or 
Oatmeal broth (ISP medium 3), from which agar had been omitted, (Pridham et al., 
1956–1957). 
 
2.5 Test organisms 
The test organisms, namely, the bacteria Escherichia coli, Pseudomonas fluorescens, 
Serratia marcescens, Staphylococcus aureus, Enterococcus faecalis and 
Xanthomonas campestris pv. campestris, and the yeast Candida utilis were all from the 
culture collection in the Department of Microbiology, University of KwaZulu-Natal, and 
included both human and plant pathogens. The former were selected on the basis of a 
1999 survey on microbial infections most commonly encountered at public hospitals in 
the KwaZulu-Natal Midlands and the latter on the frequency of bacterial infections 
occurring in the university vegetable gardens. 
 
2.6 Primary screening 
Primary screening of isolates for inhibitory action was carried out using a modified 
cross-streak method. The test organisms were streaked at right angles to the line of 
growth of the producer isolate inoculated previously and grown for six days at 30°C. 
The inoculated plates were re-incubated overnight at 30°C and the extent of inhibition 
of the various test organisms measured in millimeters. 
  
2.7 Secondary screening 
Fourteen isolates were selected for secondary screening on the basis of their inhibition 
of at least two or more of the test organisms. An exception was made in the case of 
isolates that inhibited only Pseudomonas or Xanthomonas spp., since members of 




2.8 Purification of isolates and confirmation of activity 
All isolates showing antimicrobial activity were purified using the three-way streak 
method. Purified isolates were streaked separately across the upper third of a plate of 
either Iso-sensitest agar or Mueller-Hinton agar and the same test organisms cross-
streaked to confirm the original screening results (Lancini and Parenti, 1982). 
 
2.9 Bioassay methods 
2.9.1 Agar well-diffusion method 
Samples of the culture filtrates were assayed for antimicrobial activity using a 
modification of the agar well-diffusion method of Paik and Glatz, (1995).  After 
aseptically pouring the agar (5 mm deep), plates were incubated overnight at room 
temperature before a well (7 mm diameter) was cut in the centre of each plate. The 
plates were dried by further incubation at 37°C for 2 hours to facilitate sample diffusion 
through the agar. Culture filtrate (50 µl) was transferred to the well with a micropipette 
and the test organisms streaked radially outwards, starting 1 mm from the edge of the 
well. The plates were incubated at 30°C for 24 hours and observed for growth inhibition 
zones. All assays were carried out in triplicate. Plates in which the wells were filled with 
uninoculated culture medium served as controls. 
 
2.9.2 Agar disk-diffusion method 
Some samples were also tested using the agar disk-diffusion method of Eckwall and 
Schottel, (1997). Sterile commercial paper disks were spotted with 50 µl culture filtrate 
and allowed to dry before placing on the surface of solid Mueller Hinton medium in 
Petri dishes freshly seeded with the test organism. The plates were incubated at 30°C 
for 24 hours before the diameters of growth inhibition zones were measured. All assays 
were carried out in triplicate. Plates in which the disks were impregnated with either 
solvents or uninoculated culture medium served as controls. 
 
2.9.3 Broth micro-dilution [Minimum inhibitory concentration (MIC)] 
Minimum inhibitory concentration (MIC) was determined using the broth micro-dilution 
method as recommended by the Swedish reference group for antibiotics (SRGA) and 




protocol of Hancock‟s doubling dilution method (Hancock, 1999; Weigand et al., 2008) 
or according to the protocol recommended by the Clinical and Laboratory Standards 
Institute (CLSI) [formerly National committee for clinical laboratory standards (NCCLS, 
1991 and 2004)]. The indicator test organisms were prepared by growing them in 
Nutrient broth (NB) or Mueller-Hinton (MH) broth to an optical density (OD) of 0.5 at 
420 nm, whereafter X µl cell suspension was added to 1 ml NB/ MH. The value of X 
was calculated using the equation:  X µl = 10/OD. 
 
Prior to testing, either 100 µl or 50 µl of the cell suspension was diluted in 10 ml or 5 ml 
NB/ MH, respectively. Dilutions of the antibiotic-producer culture filtrate (stock solution) 
were prepared in a micro-titre plate (10× 10 wells). From the stock solution, nine 
dilutions were made using the growth medium as diluent. A step-wise dilution factor of 
2 (1.0, 0.5, 0.25, etc.) was used throughout the dilution procedure. Finally, 100 µl of the 
prepared suspension of the indicator test organism were added to each of the wells in 
the micro-titre plate and incubated at 30°C. The plates were examined for growth after 
12 h, 24 h and 48 h incubation. The highest dilution showing no visible growth, i.e. a 
clear medium, was regarded as the MIC.  
 
2.10 Taxonomy 
Physiological, morphological, and chemical studies were carried out on eight selected 
isolates. Selection was based on sizes of inhibition zones greater than 3 mm on at 
least two or more test organisms, especially Pseudomonas fluorescens and 
Xanthomonas campestris pv. campestris that are resistant to many commonly used 
antibiotics. Morphological studies were carried out with a Carl Zeiss Axiophot light 
microscope and a Hitachi S–570 scanning electron microscope (SEM). The 
diaminopimelic acid (DAP) isomer in the cell wall was determined by the method of 
Becker et al., (1965). Carbon source requirements were studied by the method of 
Nitsch and Kutzner, (1973). The whole cell sugar pattern (WCSP) was obtained by a 
combination of the methods of Murray and Procter, (1965) and Staneck and Roberts 
(1974). 
 
2.11 Strain N8 
Strain N8 was selected from among 2600 isolates obtained during an actinomycete-




Wallis, 2007) and which is described in Chapter 3. Stock cultures were kept on 
Nutrient agar (NA) slants or stored frozen in glycerol at -80oC. 
 
2.11.1 Isolate N8 growth curve 
An overnight culture of N8 (10 ml) was seeded into 200 ml of Nutrient Broth (NB). The 
broth was shaken in a waterbath at 30oC. Aliqouts (5 ml) were removed initially and 
thereafter at 30 minute intervals and the absorbance measured at 550 nm. This 
wavelength was used to monitor the increase in cell biomass since NB grown bacterial 
cultures absorb light optimally at that wavelength (Appendix 3). A portion of each 
sample was kept in a refrigerator at 4oC for in vitro bioassay. 
 
2.12 Antibiotic production and recovery 
All steps used in the recovery process are shown in Figure 2.2. 
 
2.12.1 Shake flask fermentation 
Growth from a mature slant culture of strain N8 was inoculated aseptically into 250-ml 
Erlenmeyer flasks each containing 100 ml of production media as described in Section 
SHAKE CULTURE 
CELL-FREE BROTH 
AQUEOUS/ ORGANIC LAYERS 
 PPT/ AQUEOUS/ ORGANIC SOLUTION 
AQUEOUS/ORGANIC SOLUTION 
Acetone added (1:1) and 
extraction repeated 3X 
Ethyl acetate added (1:1) and 
Aqueous layer discarded 
Centrifuged for 15 min at 9000 
X g. Filtered and concentrated 
Fig. 2.2 Protocol used for extraction of the antibiotic produced by strain N8 
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Grown in Nutrient broth at 30
o
C for 10 days 
Centrifuged for 15 min at 9000X g and filtered 
 
Petroleum ether added (1:1) and 
extraction repeated 3X 
Organic layer discarded   
BIOASSAY 
PH of separate aliquots adjusted to 3 









2.4.3 and incubated in a New Brunswick rotary shaker at 30°C and 250 rpm for 2 days. 
The seed culture (10 ml) was transferred into 200 ml of the same medium in a 500-ml 
flask and incubated at 30°C for 14 days under agitation at 250 rpm. After incubation, 
the cultures were centrifuged in a Heraeus Labofuge 200 at 9500×g for 15 minutes. 
Aliquots of the supernatant (5 ml) were filter-sterilized (Cameo 25 AS acetate 
membrane) into sterile screw-capped glass vials. The filtration procedure was repeated 
to ensure that supernatant (culture filtrate) used for the antimicrobial activity bioassay 
was cell-free. Altogether ten litres of culture were produced in 50 flasks. 
 
2.12.2 Solvent extraction 
A three-solvent system comprising petroleum ether, acetone and ethyl acetate, was 
used for the recovery of the antibiotic from the broth. The non-polar solvent, petroleum 
ether, was used to remove lipids from the broth.  Acetone precipitation helped to 
remove most solutes from the broth and ethyl acetate was used for extracting the 
remaining polar-organic substances. A ratio of 1:1 for solvent and broth was used and 
the extraction procedure was repeated three times. The first solvent, petroleum ether 
(PE), was added to the cell-free broth, the mixture shaken thoroughly and left overnight 
to settle. Separation of the organic and aqueous layers was achieved by means of a 
separating funnel. The PE extract was tested for antimicrobial activity before being 
discarded. The second solvent, acetone, was added and the resultant precipitate 
removed by centrifugation at 9000xg for 15 minutes. The precipitate too was tested for 
antimicrobial activity by redissolving in methanol (10ml) and following the agar disk-
diffusion method of Eckwall and Schottel, (1997) described in Section 2.9.2. The 
remaining solution was concentrated 10 fold with a BUCHI rotary evaporator set at 
30oC. Finally, the solution was extracted with an equal volume of ethyl acetate (1:1). 
The aqueous layer was discarded after establishing through bioassay that the 
antimicrobial agent was in the ethyl acetate extract. 
 
2.12.3 PH precipitation 
Separate aliquots from the cell-free broth were adjusted to pH 3 and 8.2 with 2N HCL 
and 2N NaOH respectively, and then concentrated in vacuo, with a BUCHI Rotavapor 
EL 130 at 30oC or left overnight in a refrigerator set at 4oC to crystallize. The crystals 




ambient temperature. Two bioassay methods, agar well- and agar disk-diffusion, were 
used to monitor the antimicrobial activity of the extracts. The above procedure led to an 
efficient recovery of the antimicrobial compound. 
 
2.13 Purification by chromatography 
Various chromatographic techniques were tried to purify the antibacterial agent present 
in the ethyl acetate extract. 
 
 2.13.1 Flash column chromatography (FCC) 
Initially, flash column chromatography (FCC) was used to separate the compound(s) 
with antibiotic activity. Freeze-dried samples were loaded onto a column packed with 
silica gel (Merck 60) as solid support and eluted with various solvents, namely: 
methanol, ethyl acetate, acetone, petroleum ether and n-hexane. Each fraction was 
evaporated to dryness using a BUCHI Rotavapor EL 130 at 30oC and then 
resuspended in 1ml methanol before testing for biological activity. 
 
2.13.2 Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) was carried out on each extract using coated Merck 
Kieselgel 60 F254 plastic sheets. Various solvent systems (SS1 – SS5), ranging from 
strongly polar to non-polar, were used in attempts to optimize the eluting process. 
These were: Methanol: Ethyl acetate (80:20) – SS1; Ethyl acetate: Methanol (85:15) – 
SS2; Ethyl acetate: Petroleum ether (80:20) – SS3; Dichloromethane (100) – SS4; and 
n-Hexane: Ethyl acetate (20:80) – SS5. 
 
Thin layer chromatography plates were visualized, first by checking for fluorescence 
under ultraviolet (UV) light at 254 nm, or after staining with anisaldehyde, and drying 
with a heat gun. To recover any biologically-active compound(s) from the TLC plates, 
all visible bands were excised from the TLC chromatogram, the matrix (silica gel) 
packed into a Pasteur pipette and eluted through glass wool using ethyl acetate. The 
samples were evaporated to dryness in a BUCHI Rotavapor EL 130 at 30oC and 





2.13.3 Harrison research chromatotron (HRC) 
The biologically-active extract was further purified by the Harrison research 
chromatotron technique. A column plug was used to remove all impurities in the sample 
before loading into the chromatotron. As before, petroleum ether was first added to 
remove non-polar compounds in the sample. Ethyl acetate was then gradually 
introduced up to 100%. The third solvent, methanol, was added to remove non-mobile 
components. Care was taken not to increase the concentration of methanol beyond 
50% because of its tendency to dissolve the silica gel on chromatotron plates. In 
attempts to increase the concentration of the antibiotic, 30 fractions collected at 1min 
intervals were pooled into six groups (A – F) consisting of five fractions each. The 
samples were evaporated to dryness in a BUCHI Rotavapor EL 130 at 30oC and 
resuspended in 1 ml methanol before testing for biological activity. 
 
2.13.4 High performance liquid chromatography (HPLC) 
High performance liquid chromatography (HPLC) was carried out under both isocratic 
and gradient conditions using the procedures reported by Schreiber et al. (1988) and 
Joshi (2002). The HPLC procedure was repeated to provide as much material as 
possible for structural elucidation and synergistic activity testing. 
 
2.13.4.1 Isocratic high performance liquid chromatography (IHPLC) 
The isocratic HPLC analysis was conducted on active extracts using a Data Apex 
Clarity chromatography station. Fifty microlitres of extract were injected into an Alltech 
C-18 column (3.9mm X 300 mm) followed by isocratic elution with constant 
concentrations of methanol in water throughout the separation run. Five separations 
were carried out on decreasing concentration of methanol in water (100%, 80%, 70%, 
60% and 50% respectively). Elution was monitored at 280 nm. Column output was 
manually collected, and each aliquot was subsequently concentrated in a BUCHI 
Rotavapor EL 130 at 30oC. The concentrates were dissolved in minimal methanol 
before bioassay. Pure methanol was used as the control during the bioassay. However, 






2.13.4.2 Gradient high performance liquid chromatography (GHPLC) 
N8 extract was subjected to a gradient high pressure liquid chromatography (GHPLC) 
analysis to improve separation of the peaks thereby achieving higher purity of the 
compounds through separation with a Thermo Separation Products automated fraction 
collector. Various separations were carried out at decreasing concentrations (80%, 
70%, 60%, and 50%) of methanol in water. Separations were performed on active 
preparations from the N8 extract using a Varian Analytical Instruments (CA, USA) 
HPLC station equipped with a Prostar 240 pump and a Spectra System variable 
wavelength UV detector model 3000HR. A Hypersil 5 octadecylsilane (ODS) analytical 
column (25 cm x 10 mm) purchased from HPLC Technology Ltd, Cheshire, UK was 
used. Absorbance was monitored at 280nm on a C-18 reverse-phase column. 
 
The samples were eluted at a flow rate of 0.7 ml. min-1 over a total time of 45 min. 
Peaks were collected with an automated fraction collector and assayed for growth 
inhibitory activity against the test organisms. 
 
2.14 Structural elucidation methods 
2.14.1 Gas chromatography-Mass spectroscopy (GC-MS) 
Mass spectra were recorded on a ThermoFinnigan Trace GC coupled to a PolarisQ 
mass spectrometer. The column used was 30m x 0.25mm internal diameter with a 
0.25μm stationary phase film containing 5% phenyl (equivalent) / 95% methyl 
polysilphenylene / siloxane. The mobile phase was helium gas. Low and high 
resolution mass spectra were measured using a Kratos MS 80 RF double focusing 
magnetic sector instrument at 70 eV. Spectra were obtained using electron impact (EI) 
and chemical ionization (CI) modes. 
 
2.14.2 Liquid chromatography-Mass spectroscopy (LC-MS) 
The sample was diluted to a concentration of 2-5 ng/μl (sample dependant) in HPLC 
grade methanol and introduced by direct infusion into a Mass spectrometer (Waters® 
Micromass® LCT PremierTM, Time-of-Flight (TOF)) by means of a syringe pump. The 
conditions were as follows: capillary voltage: 2500 kV; cone voltage: 20 kV; desolvation 
temperature: 180°C; desolvation gas flow rate: 500 L/hr. The sample was ionised using 




2.14.3 1H- and GCOSY- Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were recorded on a Bruker Avance III spectrometer fitted with a 5mm 
BBOZ probe using deuterated methanol as solvent and residual protonated methanol 
as the internal standard. The chemical shifts were recorded in parts per million (ppm, δ) 
and the coupling constants at 500 mHertz (MHz). Details of the experimental conditions 
were as follows: Operating temperature 30 °C; Proton spectra recorded at 64K (F2), 
AQ 3.17 seconds, SW 20.66 ppm, D1 2.5 seconds, NS 256; GCOSY spectra recorded 




CHAPTER 3  
 
ISOLATION AND SCREENING FOR ANTIMICROBIAL ACTIVITY 
OF RARE ACTINOMYCETES FROM NATURAL HABITATS IN 
KWAZULU–NATAL* 
3.1 Introduction 
For the last five decades, antibiotics have revolutionized medicine by providing cures 
for life-threatening infections (Cohen, 2000).  Lately, however, there has been a 
growing concern about the emergence and management of antibiotic-resistant bacteria 
(Jack, 1996; Chopra et al., 1997).  Most of the commonly used antibiotics in our 
hospitals have become ineffective due to these resistant bacteria. The need to discover 
and develop more-effective antibiotics with unique modes of action is greater than ever 
(Kong et al., 1998). 
 
KwaZulu-Natal province of South Africa is a potentially rich field for the discovery of 
new antibiotic-producing microorganisms (Baecker and Ryan, 1987).  For example, the 
organism, Streptomyces natalensis, an actinomycete first used in the industrial 
production of pimaricin, was originally isolated from KwaZulu-Natal soil (Wang et al., 
2006). However, interest waned in this area as the number of secondary metabolites 
identified as „novel‟ decreased. Unsurprisingly, researchers had concentrated on the 
compounds produced by members of the Streptomyces genus and thus the probability 
of finding novel compounds became increasingly remote. 
Interest then switched to the rarer actinomycetes as potential sources of novel 
bioactive metabolites (Lynda et al., 2002; Cook and Meyers, 2003; Boudjella et al., 
2006) and methods designed to isolate (Pisano et al., 1986; Hayakawa and Nonomura, 
1989; Labeda, 1990; Kizuka et al., 1997) and identify (Staneck and Roberts, 1974; 
Harvey et al., 2001; Lynda et al., 2002) a wide variety of such actinomycetes have 
been developed. 
___________________ 
* Parts of this chapter have been published in the South African Journal of Science, 103, 216 – 




Modern isolation methods involve five steps: choice of a substrate (Pisano et al., 1987; 
Kitouni et al., 2005;), composition of the isolation medium (Houang et al., 1983; 
Hayakawa and Nonomura, 1984), pre-treatment and incubation conditions (Pisano et 
al., 1986), colony selection (Williams and Davies, 1965; Nolan and Cross, 1988; Hotta 
and Okami, 1996) and, finally, purification (Paik and Glatz, 1995; Hotta and Okami, 
1996). Of these factors, composition of the isolation medium, pre-treatment and 
incubation conditions are the most important, since they determine which organism will 
develop on the isolation plates (Nolan and Cross, 1988). 
 
Actinomycetes are mainly aerobic soil inhabitants and are widespread in nature 
(Lancini and Lorenzetti, 1993). The terms „rare actinomycetes‟ or „rare actinos‟ refers to 
those genera less easily detected than Streptomyces. No clear-cut habitat preference 
can be established for the different genera of rare actinomycetes; however, some, such 
as Micromonospora or Actinoplanes, are more abundant in decaying plant material or 
muddy soils on freshwater shores. Thermophilic species are often found in natural 
warm habitats, such as compost or hay mounds (Lancini and Lorenzetti, 1993). 
 
The aim of the present study is to continue the search for new antibiotic producers in 
KwaZulu-Natal by targeting rare actinomycetes using improved isolation methods. 
Members of the genus Streptomyces were excluded from the search, because they 
have been extensively studied in the past (Okami and Hotta, 1988; Miyadoh, 1993; 
Ntuli, 1994). 
 
3.2 Materials and methods 
3.2.1 Bacterial isolation 
Soil samples were collected at depths of 0–5 cm below the surface from various sites in 
the KwaZulu-Natal Midlands (Table 3.1). The storage and preparation of the samples is 
described in Sections 2.2 and 2.3. All the media used and procedures involved for 





3.2.2 Primary screening 
Screening of isolates for inhibitory action was carried out using a modified cross-streak 
method as described in Section 2.6. Purification of the isolates showing antimicrobial 
activity was carried out using the three-way streak method as described in Section 2.8. 
 
3.2.3 Secondary screening 
The production of antibiotics by the organisms was previously discussed in Section 
2.12. Samples of the culture filtrates were assayed for antimicrobial activity using a 
modification of the agar well-diffusion method of Paik and Glatz, (1995) which was 
described in Section 2.9.1. Some samples were also tested using the agar disk-
diffusion method of Eckwall and Schottel, (1997) described in Section 2.9.2. 
 
Minimum inhibitory concentration (MIC) was determined using the broth micro-dilution 
method as recommended by the Swedish reference group for antibiotics (SRGA) 
[Olsson-Liljequist et al., 1997] and its sub-committee on methodology and as per 
standard protocol of Hancock‟s doubling dilution method (Hancock, 1999) as described 
in Section 2.9.3. 
 
3.2.4 Taxonomy 
Physiological, morphological, and chemical studies on eight selected isolates were 
carried out as described in Section 2.10. 
 
3.3 Results 
The number of antibiotic-producing isolates varied with the sample source and the 
isolation pretreatment applied. Eighty of the approximately 2600 isolates screened, 
showed some antimicrobial activity. The highest number of active isolates came from 
the Forest site, while the lowest number came from the Riverine soil sample. 
Calculation of the number of antimicrobially active isolates in the total number of 
isolates screened from the various samples showed that the number of culturable 
antibiotic-producing microorganisms constituted only about 3% of the total overall 





The average inhibition zone size was sometimes different for the secondary screening 
stage, but the spectrum of activity of the respective isolates remained unchanged from 
those recorded in the primary screening phase. Some of the isolates lost a substantial 
part of their activity on extended incubation. Isolated colonies, which grew within an 
inhibition zone, were recorded as resistant variants of the strain (Table 3.2 and Fig. 
3.1A). Isolate N8 inhibited all the test organisms in the primary screen on both NA (Fig. 
3.1A) and ISTA plates (not shown). This broad-spectrum inhibition was verified during 
secondary screening on MH medium (Fig. 3.1B), with uninoculated MH medium in the 
wells serving as a control (Fig. 3.1C). Surprisingly, this isolate showed no visible 
activity against the test organisms during secondary screening using the agar-well 
diffusion method. However, the disk-diffusion method, with Serratia marcescens as the 
test organism, gave positive results (Fig. 3.1D). In some cases, discoloration of S. 
marcescens was also observed. 
 
Isolate N2 showed highest activity against P. fluorescens with an MIC of 0.0039 µg/ml, 
whereas the MIC for X. campestris pv. campestris was 0.25 µg/ml (Table 3.3). Isolate 
N8 showed good antimicrobial activity against all the test organisms used especially 
the Pseudomonas and Xanthomonas species, with MICs of 0.0625 µg/ ml and 0.0025 
µg/ ml, respectively (Table 3.3). Isolates N33 and N35 were also strongly inhibitory, 
with values of 0.002 µg/ml and 0.0039 µg/ml against P. fluorescens and X. campestris 
pv. campestris, respectively. The MIC results for all the selected antimicrobially active 
isolates against the test organisms are shown in Table 3.3. Isolate N16 inhibited four of 
the seven test organisms namely S. aureus (0.125 µg/ml), E. coli (0.0039 µg/ml), P. 
fluorescens (0.0039 µg/ml) and X. campestris pv. campestris while isolate N19 
inhibited three of the seven test organisms including P. fluorescens (0.125 µg/ml), C. 
utilis (0.25 µg/ml) and X. campestris pv. campestris. Isolate N12 and N30 inhibited only 
P. fluorescens. The results for N16 were better against P. fluorescens and X. 
campestris pv. campestris than those of N8 whereas the MIC result for isolate N2 
against P. fluorescens (0.0039 µg/ml) was better than that against X. campestris pv. 
campestris (0.25 µg/ml). 
 
The physiological, morphological, and chemical characteristics of all isolates showing 
antimicrobial action are presented in Table 3.4. Isolate N8, which had the broadest 
spectrum of activity, formed colonies with no aerial mycelium on NA. When young, the 




round to oval dome-like bodies or vesicles were formed (Fig. 3.2A). The smooth-
surfaced spores were produced in dense clusters contained in a thick sheath of 
extracellular material or inside the vesicles (Fig. 3.2B). In broth culture, the hyphae 
merged together to form synnemata, but when dried, extensive branching fragments 
were observed. The isolate could not utilize raffinose and rhamnose as carbon sources 
and no diffusible pigments were formed in either solid or liquid media. The cells were 
non-acid fast and catalase-positive. Optimum growth occurred between 27°C and 
30°C. 
 
High-performance amino-acid analysis (Beckman 6300 analyser) showed that N8 
contained substantial amounts of L- or meso-DAP. None of the diagnostic sugars for 
specific actinomycetes was present in the whole cell hydrolysate. Environmental 
scanning electron microscopy revealed that N8 spores are enclosed in a thick slimy 
layer which, when disrupted, exposes the spore mass. Scanning electron microscopy 
(SEM) revealed the smooth-surfaced, oval to rod-shaped spores. 
 
A characteristic morphological feature of isolate N35 was the coryneform-like angular 
arrangement of bacillary elements as revealed by SEM (Fig. 3.3A) with some of the 
rod-like elements measuring up to 4 µm in diameter (Fig. 3.3B). 
 
The spectra of activity of the isolates showed that N2, N8 and N16 were active against 
both Gram-positive and Gram-negative bacteria (Fig. 3.4). Isolate N8 produced a 
broad-spectrum antibiotic(s) active against both bacteria and fungi (yeasts), whereas 
N35 was inactive against Gram-positive bacteria. 
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No. Isolates per pre-treatment 
 
Total no. isolates 
screened 
 




Chicken manure [CM] 
H +A                    38 
H + NA                46 
NH +A                 94 














Chicken litter [CL] 
H +A                    34 
H + NA                61 
NH + A              123 














Cow manure [COW] 
H + A                   43 
H + NA                55 
NH + A                58 














Compost soil [CS] 
NH +A                 45 








Uncultivated farm soil [US] 
NH + A                56 
H + A                  23 











River bank soil [RB] 
NH + A                13 
NH + NA              45 
















No. Isolates per pre-treatment 
 
Total no. isolates 
screened 
 
No. Isolates active 
 
% 




 forest soil [SF] 
NH + A                97 
NH + NA            167 
H + A                   66 













Creosote-contaminated soil (CCS) NH + NA                5 5 1 20.00 
 
 
Sweet waters (dry soil) [SW] 
NH + A                71 
NH + NA            128 











Illovo sugarcane field [CSF] 
NH + A              101 
NH + NA            169 
H + A                   56 























*Escherichia coli, Pseudomonas fluorescens, Serratia marcescens, Staphylococcus aureus, Enterococcus faecalis, Xanthomonas campestris pv. campestris 
and Candida utilis; NH = non – heated; H = Heated; A, antibiotics added; NA, no antibiotics added.   




 dilutions of the sample.  
†
South African Paper and Pulp Industries.  
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Table 3.2 Average inhibition zone sizes (mm) of selected isolates* against test organisms^ on primary screening 
Isolate* Source Test organisms^ 


























































































































































































Isolate* Source Test organisms^ 










































































^Sa, Staphylococcus aureus; Ec, Escherichia coli; Pf, Pseudomonas fluorescens; Sm, Serratia marcescens; Ef, Enterococcus faecalis; Cu, 
Candida utilis; Xc, Xanthomonas campestris pv. campestris; Rs, Resistant variant; CL, Chicken litter; CM, Chicken manure; CS, Compost soil; SW, 
Sweet waters (dry soil); nt = not tested; -Dc, discoloration;  –, no inhibition; H, heated; NH, non-heated; A, antibiotics added; SF, SAPPI forest; 
CSF, sugarcane field; *selected for secondary screening. 
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Table 3.3 Minimum inhibitory concentrations (μg/ml) of the selected antimicrobially active isolates against the test organisms 
 
Isolate Test organisms 

































































































































*uns, unsusceptible; nt, not tested; Sa, Staphylococcus aureus; Ec, Escherichia coli; Pf, Pseudomonas fluorescens; Sm, Serratia marcescens; Ef, 
Enterococcus faecalis; Cu, Candida utilis; Xc, Xanthomonas campestris pv. campestris. 
82                                                                                                                                                                                                                                   
           
                                                                                           
Fig. 3.1 Inhibition of test organisms by isolate N8: A, inhibition of test organisms on primary screening 
(arrow shows resistant variants); B, confirmation of inhibition on MH agar; C, control showing uninhibited 
growth of test organisms on MH agar; D, inhibition of Serratia marcescens by N8 purified extract on 
secondary screening. Test organisms include: Staphylococcus aureus (1), Escherichia coli (2), 
Pseudomonas fluorescens (3), Serratia marcescens (4), Enterococcus faecalis (5), Candida utilis (6) 
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+ = Positive; – = negative; nt = not tested; NA = Not applicable; WCSP = Whole-cell sugar pattern; Ara = Arabinose; Gal = Galactose; NC = No Characteristic sugar; 
*YBR=Yellow-Brown-Red;
 a




 appear as doublets with tapered ends. 
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Fig. 3.2 Growth of N8 culture on Nutrient agar: A = mature mycelium (arrow shows dome like 
body or spore vesicles); B = Scanning electron micrograph of mycelium (arrow shows oval 
shaped spores exposed inside a broken vesicle). 
 
 
         
 
 
Fig. 3.3 Scanning electron micrograph of isolate N35: A = Angular arrangement of bacillary 








































Xanthomonas campestris pv campestris




Enumeration of the exact number of colonies isolated in this investigation is not 
possible, since many of the organisms that were obviously non-actinomycetes were 
disregarded. However, a rough estimate of the scale of the isolation programme may 
be obtained by considering the number of plates used. For each of 10 samples 
investigated, three dilutions (10–2 to 10–4) were prepared and divided into four equal 
aliquots and each aliquot was subjected to a different treatment before plating on 
triplicate plates of at least seven appropriate isolation media. There were four treatment 
conditions as shown in Table 3.1. Thus, a total of 10 × 3 × 4 × 3 × 7 = 2520 isolation 
plates were used in this investigation. 
 
Heat pretreatment of the samples was beneficial as it eliminated most of the unwanted 
Gram-negative bacteria that produce mucoid, spreading colonies on soil dilution plates 
(Williams and Wellington, 1982), thereby facilitating the isolation of actinomycetous 
organisms. The addition of antibacterial antibiotics such as gentamicin, streptomycin 




actinomycetales. The combined treatment of heat and antibiotic incorporation into the 
media eliminated most of the unwanted fungi, yeasts and eubacteria and consequently 
reduced the number of colonies developing on the plates. 
 
The disadvantage of adding antibiotic(s) to the isolation media is that potent antibiotic 
producers, sensitive to the antibiotic added, might be inhibited, and hence remain 
undetected. On the other hand, the antibiotic(s) makes the medium more selective by 
limiting the types of organisms developing on the plates. Different members of the 
actinomycetales differ significantly in their sensitivity toward antibacterial antibiotics. 
Streptomycetes fortunately belong to the antibiotic-sensitive group (Williams and 
Davies, 1965; Jawetz et al., 1984), making it easier to target the rarer actinomycetales. 
 
Some of the isolation media used, namely Winogradsky‟s nitrite medium (Winogradsky, 
1949), M3 medium (Rowbotham and Cross, 1977), and Kosmachev‟s medium 
(Kosmachev, 1960), were found to be selective for actinomycetes without heat pre-
treatment and/or antibiotic incorporation, although a few colonies of other bacteria did 
occasionally develop on the plates. Thus, the selectivity of some of the so-called 
selective media used in this study is questionable. 
 
Although the media used in this investigation were not compared directly, some 
differences were nonetheless evident. Modified Czapek‟s agar appeared to enhance 
pigment-producing strains of actinomycetes, most probably the Nocardioform group. 
MGA supported growth of mainly filamentous organisms. Of all the media used, 
Kosmachev‟s medium appeared to be the most selective, as most of the plates 
contained virtually pure cultures of non-streptomycetous actinomycetes. This medium 
has been reported to be selective for Excellospora and related genera (Kosmachev, 
1960). 
 
Screening results indicate that forest sites, with their usually high organic content and 
acidic nature, may offer a good hunting ground for antibiotic-producing 
microorganisms, especially in KwaZulu-Natal. Waksman and his co-workers in 1942 
reported the presence of antibiotic-producing microorganisms in acidic forest soils. The 
soil samples from the riverine site were waterlogged and hence devoid of oxygen, thus 




Our negative results with this soil may also reflect an inability of the media used to 
support growth and/or antibiotic production by the riparian microbiota. 
 
Many of the other samples screened, such as compost soil, cow and chicken manure, 
and sugar-cane field soil, were rich in organic matter and contained a large variety of 
actinomycetes. As could be expected, the dry, uncultivated soil sample also contained 
many actinomycete isolates, since it has been reported that most arid soils usually 
have an alkaline pH and contain a number of the rare actinomycetes (Kizuka et al., 
1997). These authors reported on the distribution of actinomycetes in South African 
soils in 1997. Apart from this report, current quantitative data on the geographical and 
ecological distribution of actinomycetes in South Africa is scarce in the scientific 
literature. 
 
Results of the present studies confirm the contention that it is erroneous to compare 
one antibiotic agent against another on the basis of inhibition zone size, since the size 
and position of the growth inhibition zone are a consequence of many dynamic 
systems, including diffusion rate, proceeding simultaneously (Linton, 1983). The 
observed discoloration of Serratia marcescens was not the result of metabolic 
interference, as incubation at a lower temperature restored the characteristic red 
colour. The resistance of Enterococcus faecalis to most of the isolates tested, with the 
exception of isolate N8, may have been a medium affect or the strain of Enterococcus 
faecalis used may produce an enzyme, which inactivated any antibiotic produced or 
due to an efflux pump that expelled the antibiotic (Salyers and Whitt, 2005). 
 
The loss of some activity during secondary screening using the agar well-diffusion 
method could be ascribed to procedural effect, including preparation of the culture 
filtrate, media composition, and incubation conditions. Another explanation may be that 
in the primary screens actively growing cells (with ongoing antibiotic production) were 
used, whereas cell-free filtrates were used in the secondary screening protocol and a 
large amount of antibiotic or antibiotic activity may have been lost. Furthermore, losses 
might occur if the active compounds are labile. 
 
The MIC values shown in Table 3.3 serve as an index of the relative antimicrobial 
activity and the antimicrobial spectra of the isolates. After a lot of thought, isolate N8 




test organisms used in this investigation. It also showed larger diameter inhibition 
zones than another active isolate, N2. Furthermore, isolate N2 did not inhibit a resistant 
strain of Enterococcus faecalis and the inhibitory activity it showed against Serratia 
marcescens during primary screening was not confirmed during secondary screening 
whereas with N8 it was.  
 
The loss of some activity during secondary screening using the agar well-diffusion 
method could be ascribed to procedural effect, including preparation of the culture 
filtrate, media composition, and incubation conditions. Another explanation may be that 
in the primary screens actively growing cells (with ongoing antibiotic production) were 
used, whereas cell-free filtrates were used in the secondary screening protocol and a 
large amount of antibiotic or antibiotic activity may have been lost. Furthermore, losses 
might occur if the active compounds are labile. 
 
Comparisons with descriptions of actinomycetales genera in Bergey‟s Manual of 
Systematic Bacteriology (Lechevalier, 1989) showed N8 to closely resemble members 
of the Nocardioides group. However, unlike N8, Nocardioides produce aerial mycelium 
that ultimately fragments. Hence, the isolate is unlikely to belong in this group. The 
absence of diagnostic sugars in whole-cell hydrolysates (WCSP C) of isolate N8, the 
presence of L-DAP (wall chemotype I), the formation of substrate mycelium with round 
to oval spore-like bodies and vesicles, together with other cultural and physiological 
properties listed in Table 3.4, placed N8 in the genus Intrasporangium. 
 
Similar approaches to those described above were used to identify tentatively isolates 
N2, N12, N16, N19 and N35 as Thermomonospora sp., Saccharopolyspora sp., 
Nocardia sp., Corynebacterium sp. and Promicromonospora sp., respectively. 
 
3.5 Conclusions  
These preliminary findings confirm that KwaZulu-Natal soils harbour antibiotic-
producing microorganisms, as shown by previous investigators (Baecker and Ryan, 
1987; Ntuli, 1994; Kizuka et al., 1997; Wang et al., 2006), and that it could be 
worthwhile undertaking a more comprehensive search for rare forms of antibiotic-





Of all the isolates assayed in the present investigation, N8, tentatively identified as an 
Intrasporangium species, appears to have the greatest potential. The results obtained 
from screening and MIC determinations showed it to be active against all the test 
organisms used, especially the Pseudomonas and Xanthomonas species, with MICs of 
0.0625 μg/ ml and 0.0025 μg/ ml, respectively. However, specificity of action by 
antibiotics is often favoured by medical science (Jawetz et al., 1984). It may be that the 
substance(s) produced by isolate N8 is/are toxic to many additional microorganisms. 
The chemical nature of the antimicrobial compound(s) produced by N8 is reported in 
Chapter 5. The indications are that the major antimicrobial substance is a tryptamine. 
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CHAPTER 4 
ISOLATION AND PURIFICATION OF THE ANTIBIOTIC 
COMPOUND(S) PRODUCED BY INTRASPORANGIUM STRAIN 
N8* 
4.1 Introduction 
Solvent extraction is widely used to extract antibiotics (Alves et al., 2002; Kumar et al., 
2005). However, most antibiotic compounds exist in two main forms, as a salt or as a 
basic compound which are respectively soluble and insoluble in hydrophilic solvents. 
Therefore, a careful choice of solvent system provides a more efficient and faster 
extraction of the antimicrobial compounds from complex mixtures (Oka et al., 1998). 
 
Historically the first separations of organic mixtures were accomplished by 
countercurrent distribution (CCD) followed soon after by partition chromatography on 
paper or on columns of cellulose or Sephadex. The CCD procedure offers a high 
resolving power when the proper solvent system is used and becomes a powerful tool 
to separate the various components of antibiotic complexes (Oka et al., 1998). 
 
More recent developments in antibiotic purification include the use of thin-layer (TLC) 
and high-pressure liquid chromatography [HPLC] (Giuliano et al., 2002; Joshi, 2002). 
One of the shortcomings of chromatography is that standards are required in order to 
identify compounds in the sample and, even then, one cannot be absolutely certain of 
the identification, especially if a novel substance is involved. In contrast, spectroscopic 
techniques can give much information about the structure and identity of unknown 
substances (Giuliano et al., 2002). 
 
In this chapter the isolation and purification of an antibacterial agent produced by 
Intrasporangium strain N8 obtained from a barnyard soil in the KwaZulu-Natal 
midlands, South Africa is described. The study is part of the current worldwide search 
for new antibiotic compounds as multiply resistant organisms continue to be a threat to 
global public health (Cohen, 2000).  
 
__________________ 
*Parts of this chapter have been submitted for publication to the Canadian Journal of 
Microbiology.  
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4.2 Materials and methods 
All major steps used in the purification of the antibacterial agent are shown in Figure 
2.1. 
 
4.2.1 Organism and primary activity 
The source of strain N8 was described in Section 2.11. Stock cultures were kept on 
Nutrient agar slants or stored frozen in glycerol at -80oC. The organism was 
provisionally identified as an Intrasporagium species according to Bergey‟s Manual of 
Systematic Bacteriology (Williams et al., 1989) as was described in Section 2.10. 
Antimicrobial activity was determined in vitro by agar disk diffusion or micro-dilution 
methods as described in Section 2.9. 
 
4.2.2 Strain N8 growth curve 
The growth curve of strain N8 was established in conjunction with bioassays to 
determine the best time to harvest the antibiotic produced by the organism. The 
procedure used is described in Section 2.11.1. The results of the study are shown in 
Appendix 3 and graphically represented in Figure 4.1. 
 
4.2.3 Antibiotic production and recovery 
The fermentation and recovery procedures are described in Section 2.12. Ten litres of 
culture was produced which was centrifuged at 9000xg for 15 minutes and the 
supernatant filtered through Cameo 25 AS acetate membrane filters prior to analysis. A 
flowchart indicating all steps used in the recovery process is shown in Figure 2.2 
(Chapter 2). 
 
4.2.4 Purification by chromatography 
Various chromatographic techniques were tried during attempts to purify the 






4.3.1 Organisms and primary activity 
Isolate N8 showed good antimicrobial activity against all the test organisms used 
during the primary and secondary screening phases, especially Pseudomonas 
fluorescens and Xanthomonas campestris pv. campestris, with average inhibition zone 
diameters of 26 mm and 28 mm, respectively. Its spectrum of activity included both 
Gram-negative and Gram-positive bacteria and the test yeast, Candida utilis (Table 
4.1). 
 
Table 4.1 Spectrum of activity produced by Intrasporangium strain N8 against test 
organisms during confirmatory primary* screening 
* Screening on Mueller-Hinton (MH) agar (Oxoid), + = positive inhibition (3–10 mm); ++ = 11–20 
mm; +++ = 21–25 mm; ++++ = 26–30 mm 
 
4.3.2 Antibiotic production and recovery 
The stationary phase of growth commenced after about 58 h of incubation (Fig. 4.1). 
Antibiotic production commenced after 58 h and continued until maximum yield at 168 
h incubation at 30oC on the neutral (pH 7.0) media NB and/or ISP medium 3. 
 
Addition of petroleum ether, a non-polar solvent, successfully removed much of the 
lipids from the broth, while subsequent addition of ethyl acetate helped in extracting the 
remaining organic material from the broth. Acetone precipitation eliminated most 
solutes from the broth. Some pink-yellow needle-like crystals formed on the sides of the 
flask containing the concentrated ethyl acetate extract. The crystals showed inhibitory 
activity against Serratia marcescens (Fig. 4.2A). 
Test Organism Extent of inhibition Average inhibition  
zone diameter (mm) 
Staphylococcus aureus + 10.0 
Escherichia coli +++ 25.0 
Enterococcus faecalis ++ 20.0 
Serratia marcescens ++ 15.0 
Pseudomonas fluorescens ++++ 26.0 
Candida utilis +++ 21.0 






Fig. 4.1 Growth curve of strain N8 at 30
o
C in Nutrient broth. 
 
Thin-layer chromatography of the ethyl acetate fraction revealed three separate bands 
when viewed under UV light at 254 nm. The eluate from the upper band inhibited the 
growth of Serratia marcescens (Fig. 4.2B) and also E. coli and X. campestris pv. 
campestris (results not shown).  The middle and lower bands did not inhibit the growth 
of any of the test organisms. 
 
Bioassay results of solvent extracts showed clear inhibition zones around paper disks 
dipped in the ethyl acetate extract (EH) [Fig. 4.2C]. No zone of inhibition against the 
test organism, E. coli, was observed for the petroleum ether extract (PE). A very large 
inhibition zone (30 mm) was also observed for the alcohol extract (AH), although 
portions of the zone were cloudy compared to that of the ethyl acetate extract (EH) [21 
mm] which was clear. A slight inhibition was observed for the alcohol used as control 
(AHC) [Fig. 4.2D] and was consequently dropped as an extraction solvent. The other 
solvents, petroleum ether (PEC), acetone (ACC), and ethyl acetate (EAC) used as 
control (Fig. 4.2D) did not show inhibition against the test organism. 
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Fig. 4.2 Antimicrobial activity of Intrasporangium strain N8. A = Inhibition of Serratia marcescens 
by pink-yellow needle-like crystals of the antibiotic produced by strain N8; B = Inhibition of 
Serratia marcescens by the uppermost band on TLC chromatograms following separation of 
strain N8 culture fluid extract, EAF with SS2; C = Inhibition of E. coli by paper disks soaked in 
solvent extracts (arrow shows non-inhibition of E. coli by petroleum ether extract (PE); D = Non-
inhibition of E. coli by paper disks soaked in each of the solvents petroleum ether (PEC), 
acetone (ACC), and ethyl acetate (EAC) used as controls [arrow shows slight inhibition by 
alcohol control (AHC)]; EN = Ethyl acetate: NaCl (NaCl was added to allow for complete micelle 
removal and later discarded with the aqueous layer); EH = Ethyl acetate: H2O; AH =Alcohol: 
H2O; PE = petroleum ether. 
 
4.3.3 Purification by chromatography 
Flash column chromatography (FCC) removed most of the inactive, colored material 
from the antimicrobially-active extract. However, after passing through the column, 
some extracts appeared to be more complex than was originally thought judging from 
the number of bands observed on TLC chromatograms (results not shown). The 










with the most polar to the least polar solvent systems (SS1 – SS5). The solvent system 
SS1 eluted four bands from the ethyl acetate fraction (EAF) [Fig. 4.3A] whereas both 
the methanol fraction (MF) [Fig. 4.3B] and acetone fraction (AF) [Fig. 4.3C] contained 
only three bands. The solvent system SS2 eluted four bands each from MF and EAF 
but only two from AF. The solvent system SS3 eluted five bands from MF while SS5 
eluted three bands from EAF. There were no bands observed from any of the fractions 
run with solvent system SS4 while no separation was observed for the n-Hexane 
fraction used as a control (Fig. 4.3D). In summary, good separation from most of the 
fractions was achieved with SS2. The average Rf values of all the eluted bands are 
shown in Appendix 1. Bioassay of the chromatogram from ethyl acetate extract 
separated with the SS2 system revealed antibiotic activity in the region that had an Rf 
value of 0.56 – 0.64. 
 
The Harrison research chromatotron technique gave good separation of the 
antimicrobially-active sample. In attempts to increase the concentration of the antibiotic 
30 fractions collected at 1min intervals were pooled into six groups (A – F) as 
described in Section 2.13.3 before being tested for biological activity. Two groups (A 
and E) of the pooled fractions showed biological activity against Serratia marcescens 
(results not shown). 
 
High performance liquid chromatography (HPLC) analysis results revealed peaks [Fig. 
4.4A] that eluted within 5 minutes under isocratic conditions. When the methanol 
concentration of the mobile phase was decreased during the analysis, an increase in 
retention time was observed [Fig. 4.4B – D]. Optimal separation following isocratic 
HPLC was observed at 50% methanol concentration [Fig. 4.4E]. Although, a number of 
peaks were observed during isocratic HPLC runs, they were not as clearly separated 
as when run under gradient conditions. Three major peaks (PI, PII and PIII) [Fig. 4.5] 
were revealed when run under decreasing concentrations of methanol in water. 
Methanol concentrations between 50% and 70% in water were considered the optimum 
gradient HPLC mobile phases (Fig. 4.5B – C). A methanol concentration of 100% in 
water was not suitable (Fig. 4.5A). On further purification, the peak at 5 minutes (PII) 
was collected as pure (Fig. 4.5D) since it inhibited the growth of most test organisms 
including S. aureus, E. coli, and S. marcescens as well as M. luteus and X. campestris 
pv. campestris (Table 6.1, Chapter 6). PI and PIII were also collected as pure (results 
not shown).  
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Fig. 4.3 Separation of solvent extracts by thin layer chromatography: A, Ethyl acetate fraction; B, Methanol fraction; C, Acetone fraction; D, n-Hexane control; B1, B2, B3, B4, and B5 indicate band 
numbers 1, 2, 3, 4 and 5 respectively eluted by each solvent system (SS). SS1, Methanol: ethyl acetate (80:20); SS2, Ethyl acetate: methanol (85:15); SS3, Ethyl acetate: diethyl ether (80:20); SS4, 
Dichloromethane (100%) did not separate any of the extracts; SS5, n-Hexane: ethyl acetate (20:80). Various band positions on the chromatograms are shown by their Rf values. 
N-Hexane fraction control 
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Fig. 4.4 High performance liquid chromatograms following isocratic separation of Intrasporangium strain N8 culture fluid extract. Fifty microlitres of extract were injected into an 
Alltech C-18 column (3.9mm X 300 mm) followed by isocratic elution with constant concentrations of methanol in water throughout the separation run. A – E = Separations achieved 























Fig. 4.5 High performance liquid chromatograms following gradient separation of culture fluid 
extract of Intrasporangium N8. Fifty micro litres of extract were injected into a Hypersil 5 ODS 
analytical column (25 cm X 10 mm) followed by gradient elution in decreasing concentrations of 
methanol in water. Elution was monitored at 280 nm. The unit on the vertical axis signifies 
milliabsorbance units (mAU). A–D= Separations achieved at various concentrations of methanol 
in water [A, 80% methanol; B, 70% methanol; C, 60% methanol with three major peaks (PI – PIII) 
observed; D, 50% methanol following targeting and further purification of PII since it inhibited the 
growth of most organisms tested including S. aureus, E. coli, and S. marcescens as well as M. 
luteus and X. campestris pv. campestris (note that each of the peaks was targeted and collected 




The zone of inhibition observed during the primary and secondary screening phases is 
due to antibiotic diffusing into the medium from the paper disks impregnated with N8 
culture filtrate. Concentration of the inhibitory compound(s) decreased with distance 
from the disk, creating a concentration gradient. At a certain distance from the disk the 
concentration was minimal for any inhibition to occur, hence, an activity zone was 












inhibition zone diameter of 28 mm (Table 4.1). This result will be interesting to plant 
pathologists as the organism is notoriously difficult to contain in the field. 
 
By monitoring antibiotic production every 12 hours during the culture period, it was 
possible to establish the time of maximum antibiotic production. Most secondary 
metabolites, including antibiotics, are produced at a very late stage during growth of an 
organism (Zahner, 1979). Intrasporangium strain N8 should be grown for 7 to 10 days 
in simple medium before harvesting the broth for antibiotic separation. In this study, 
harvesting of the secondary metabolite was done on the tenth day. This ensured the 
stationary phase had been reached which is imperative since most antibiotics start 
being produced at the onset of this phase (Eckwall and Schottel, 1997). 
 
Glycerol was found to limit the multiplication of N8 cells. However, to what extent 
glycerol enhanced or decreased antibiotic yield by N8 was not evident from the 
bioassay results. This substance has been used by some authors (Hadder et al., 2007; 
Jamil et al., 2007) as a stress factor to increase antibiotic yield. 
 
The recovery and purification of the antibiotic produced by strain N8 posed a number of 
problems including the separation of compounds with different polarities. To this end, 
substances in the broth were targeted and extracted with both polar and non-polar 
solvents. Acetone precipitation helped to eliminate solutes thereby aiding extraction of 
the active compound(s) by removing a large proportion of the inactive substances. 
 
The successful extraction of the antibacterial agent with polar solvents only indicated 
that it was a polar organic molecule and not a lipid.  This is in keeping with the findings 
of other writers that the majority of antibiotic compounds are polar (Lancini and 
Lorenzetti, 1993). The polar nature of the active substance was confirmed when the 
petroleum ether extract failed to show any biological activity against the test organisms 
(Fig. 4.2C). The successful extraction of the antimicrobial agent from the broth with 
ethyl acetate led to the sole use of ethyl acetate soluble extracts (EAF) in all 
subsequent chromatographic analyses. 
 
Column chromatography is the most commonly used preparative technique for the 
isolation of chemical compounds; therefore considerable effort was expended in 




methanol, alcohol, acetone and ethyl acetate but not in hexane or petroleum ether. The 
anomaly of the extracts from column chromatography having more bands than the 
original sample could be attributed to possible decomposition of the original compound 
and formation of artifacts which resulted in a more complex chromatogram being 
obtained (Zapata and Garrido, 1991). 
 
TLC separation of the EAF repeatedly produced clearly isolated bands and the results 
obtained with all the solvent systems used were reproducible. However, the procedure 
is very laborious and time-consuming. The most important parameters viz; the 
stationary phase, vapour phase, suitable solvents, mode of development as well as 
mobile phase optimisation and transfer are selected by trial and error (Nyiredy, 2000). 
In this investigation, the strongly polar solvent system SS2 which comprised ethyl 
acetate: methanol (85:15) was found to be the most suitable eluent. The advantage of 
SS2 is that both components are volatile and are thus easily removed from the sample. 
 
The advantages of using a Harrison research chromatotron for separation are that they 
are relatively cheaper and quicker to run than TLC since less solvent is consumed and 
the components are visible as they elute (Yrjonen, 2004). In addition, the eluted 
fractions are easily pooled together for subsequent bioassay analysis. However, 
preparation of the plates is time consuming and tedious. The procedure served as the 
penultimate step in the purification protocol. 
 
Preparative HPLC was used as the final purification step for most of the EAF samples. 
The main difference between isocratic and gradient HPLC conditions is in the 
concentration of the mobile phase (Purcell et al., 1999). In the latter case, mobile 
phase concentration is important when trying to separate a mixture of two compounds 
since the separation improves with varying concentration of the solvents (Purcell et al., 
1999; Guzzetta, 2001). With gradient HPLC a suitable mobile phase combination 
makes possible the targeting and collection of particular compounds of interest often 
not possible with isocratic runs (Stoll et al., 2006). The noticeable increases in retention 
time as methanol concentration in the mobile phase decreased during HPLC analysis 
may be due to molecules adhering more strongly to the C-18 column and hence being 





The successful chemical extraction, purification and subsequent bioassay results 
confirmed that Intrasporangium strain N8 produces organic compound(s) with antibiotic 
properties and that this/these is/are readily soluble in acetone, ethyl acetate and 
methanol, but insoluble in petroleum ether and hexane thereby indicating a polar 
nature. 
 
Since the chromatographic methods used initially were time consuming, and produced 
low yields of the compound(s) of interest, an alternative procedure producing better 
results was sought. This led to the development of a three-solvent system and pH 
precipitation techniques for efficient recovery of the antimicrobially-active compound in 






STRUCTURAL ELUCIDATION OF THE ANTIBIOTIC 




Antibiotics are mainly polar compounds containing acidic or basic functional groups 
(e.g., carboxylic acids, phenols, and amines) that may be subject to direct and indirect 
breakdown during fermentation and/or isolation/purification. The result can be a 
complex mixture of intermediates and transformation products. Once released into the 
broth, antibiotics are subjected to processes (e.g., dilution, biodegradation, etc.) that 
contribute to their elimination from the broth. Hydrolytic processes are of great 
importance in determining the fate of antibiotic compounds (Petrović and Barceló, 
2007). 
 
Antibiotic identification is complicated and a cumbersome process, requiring the 
application of advanced instrumental methods (e.g., liquid chromatography (LC) with 
mass spectrometry (MS) [LC-MS], LC with ultraviolet or fluorescence (UV/FL) 
detection, nuclear magnetic resonance (NMR), matrix-assisted laser 
desorption/ionisation (MALDI)-MS, gas chromatography (GC) with mass spectrometry 
(GC-MS), ion chromatography (IC) or infrared (IR) spectroscopy. Of these, LC-MS has 
gained popularity and has become one of the preferred techniques for analysing 
antibiotics (Petrović et al., 2005). Two common strategies are applied, depending on 
the LC-MS instrumentation used. One relies on accurate measurement of molecular 
mass, and, subsequently, the determination of the empirical formula using orthogonal 
acceleration time-of-flight (oaTOF) instruments; whereas the other involves elucidation 
on the basis of structural information gained in tandem MS experiments that can be 
accomplished either by coupling mass analyzers in series (e.g., triple-quadrupole 
(QqQ)) or by using a single ion-trap (IT) analyzer (Petrović et al., 2005). 
 
The sensitivity and selectivity of modern LC-MS instruments have made this technique 
a powerful tool and as mentioned above, a method of choice for identifying antibiotic 




component is the most relevant factor in the elucidation process, especially when no 
databases are available. Another significant problem when dealing with novel 
compounds is the lack of authentic standards that can be used to confirm the structure, 
because, although LC-MS and other accurate measurement systems (e.g., LC-Qq-
TOF) can be used for compound identification, authentic standards are still needed for 
the final, definitive confirmation, as well as for quantification (Petrović et al., 2005). 
There are three basic functions that a mass spectrometer performs. Firstly it subjects 
the molecules to bombardment by a stream of high energy electrons, whereby the 
molecule is converted to its ionic form. Secondly, these ions then get accelerated in an 
electric field. Finally the different ionized fragments are detected (Hites, 1997). 
 
In addition to LC-MS, GC-MS is also a useful tool for structural elucidation of antibiotic 
compounds. It is the single most important tool for the identification and quantification 
of volatile and semi volatile organic compounds in complex mixtures (Santos and 
Galceran, 2002). As such, it is very useful for the determination of molecular weights 
and (sometimes) the elemental compositions of unknown organic compounds in 
complex mixtures (Santos and Galceran, 2002). However, the major disadvantage of 
GC-MS is that the sample must be volatile, since its components will be separated in 
the gas phase and only compounds with vapour pressures exceeding about 10-10 torr 
can be analysed. This means that usually biological samples need to be derivatised 
(Hites, 1997). Also, determining positional substitutions on aromatic rings is often 
difficult. Certain isomeric compounds cannot be distinguished by mass spectrometry 
(for example, naphthalene versus azulene), but they can often be separated 
chromatographically (Hites, 1997). 
 
To ensure qualitative identification of an organic compound using GC-MS, several 
criteria should be met. Firstly, the mass spectra of the unknown compound and of the 
authentic compound must agree over the entire mass range of the spectra. It is 
particularly important to compare the patterns within narrow mass ranges; these 
patterns should agree almost exactly. In this case, the spectrum of the authentic 
compound might come from a library of reference spectra or from the actual compound 
itself. In the latter case, the compound could be purchased or synthesized. Secondly, 
the GC retention times of the unknown compound and of the authentic compound must 
agree within about ±1 to 2 sec. It is often convenient to co-inject the unknown mixture 




correct factor. Thirdly, a compound cannot be considered fully identified in a mixture 
unless two other questions are addressed: is the identification plausible? Why is it 
present in a given sample? If identification is implausible or if there is no reason for a 
compound to be present in a sample, the identification could be wrong or the 
compound could be a contaminant (Hites, 1997). However, as mentioned previously, a 
complicating factor might be the lack of authentic standards. 
 
Another powerful tool used by many researchers to elucidate the structure and function 
of many biologically important molecules is NMR. In this investigation, correlation 
spectroscopy (COSY) and proton nuclear magnetic resonance (1H NMR) experiments 
were used for structural determination of the antimicrobial compound. COSY produces 
a 2-dimensional NMR spectrum that shows correlation between coupled protons in a 
molecule (Jacobsen, 2007). On the spectrum is a diagonal with cross peaks on either 
side that are symmetrically disposed. Two cross peaks can interact at right angles 
where the chemical shifts of two-coupled resonances can be obtained. The gradient 
correlation spectroscopy (GCOSY) spectrum indicates which of the lines in the proton 
spectrum are connected. The advantage of GCOSY is that it filters out noise and also 
is faster than normal COSY (Bendiak et al., 2002). 
 
The 1H NMR spectrum gives the coupling constants or the splitting in the peaks. A 
single peak is normally referred to as a singlet.  It is called a „doublet‟ when the peak is 
split into two and a „doublet of doublet‟ when two corresponding peaks have the same 
splitting. A „multiplet‟ refers to three or more splits within two corresponding peaks. The 
difference between two peaks at one position and two peaks at another position which 
is the same is known as the coupling constant (Hornback, 2005). It is measured in 
Hertz (Hz). A line list showing the coupling constants for the antimicrobial compound 
produced by N8 is shown in Appendix 2. In this chapter attempts to elucidate the 
structure of the secondary metabolite with antibiotic activity produced by strain N8 is 
described. 
 
5.2 Materials and Methods 
5.2.1 Liquid chromatography-Mass spectroscopy (LC-MS) 
LC-MS analysis of the crystals was carried out as described in Section 2.14.2. A three-




from the broth as described in Section 2.12. 
 
5.2.2 1H- and GCOSY- Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were recorded on a Bruker Avance III spectrometer at 30oC using 
deuterated methanol as solvent and residual protonated methanol as the internal 
standard as described in Section 2.14.3. Gradient correlation spectroscopy (GCOSY) 
spectra were recorded on the same instrument. The sample was dissolved in d-
methanol using residual protonated methanol as chemical shift reference as described 
in Section 2.14.3. 
 
5.2.3 Gas chromatography-Mass spectroscopy (GC-MS) 
Characterization of the antimicrobial substance was carried out by GC-MS analysis as 
described in Section 2.14.1. The sample was evaporated to dryness in a BUCHI 




The antimicrobial agent was successfully extracted from the fermentation medium as 
mentioned in Chapter 4 (section 4.4). Adjusting the pH of the EAF to either 3 or 8.2, 
resulted in the formation of two types of crystals; brown and pink-yellow in colour 
respectively. On further analysis using LC-MS (Fig 5.1), the brown crystals appeared to 
be a protein and since it did not show inhibitory activity against any of the test 
organisms, no further studies were carried out on it. The pink-yellow crystals when 
suspended in a minimal volume of methanol showed inhibitory activity against S. 
marcescens (discussed in Chapter 4: Fig. 4.2A). 
 
The MS spectrum (Fig. 5.2) of the pink-yellow crystals shows a prominent/base peak at 
304.2724 (mass to charge ratio (m/z) in positive mode. Analysis of this peak indicated 
that it could be C16H36N2O3. There was no matching compound in the database of 
natural products [National Institute of Standards and Technology (NIST), 
www.nist.gov].  
 




4.3, 4.4, 5.6, 6.7, 7.0, 7.4, 7.6, and 7.7 ppm. There is evidence of one or two aromatic 
protons (possibly part of a benzene ring) at positions 7 – 7.5 ppm. In addition, there is 
clear evidence of approximately six CH2 groups, about the same number of CH3 groups 
and possibly five CHOH, CHNHCO and CHR (R=alkyl) groups. 
 
The gradient correlation spectroscopy (GCOSY) spectrum of the pink-yellow crystals 
(Fig. 5.4) revealed a connection between the protons at 1.6 and 4.4 ppm or a sharing 
of the same neighbouring carbons. Similarly, the protons at 1.7 and 4.3, 5.6 and 7.4, 
6.7 and 7.0, 7.6 and 7.7 ppm are also connected. 
  
Gas chromatography-mass spectroscopic (GC-MS) data analysis of the EAF indicated 
that the substance showing antibiotic activity comprised at least seven components 
labeled A – G in Figure 5.5. These components separated by gas chromatography 
were then subjected to mass spectrum analysis and their retention indices compared to 
computer database listings of known compounds [National Institute of Standards and 
Technology (NIST), www.nist.gov]. Although A and B have different retention indices, 
their molecular weight and formula are the same and therefore they were regarded as 
representing a single compound. Thus a total of six different compounds were detected 
by GC and their molecular formulae elucidated as: C6H10O (A and B); C6H12O2 (C); 
C9H14O (D); C8H7N (E); C21H44 (F); and C12H14N2O (G). The closest match from the 
computer database of known compounds [National Institute of Standards and 
Technology (NIST), www.nist.gov] was found for C12H14N2O (G) with 71% probability 
(Table 5.1) and identified as N-[2-(1H-indol-3-yl) ethylacetamide (Fig. 5.6A; Fig. 5.6B). 
The putative identities of A – G are also shown in Table 5.1. Since low probability 
matches were obtained for A – E and as the sample could not be recovered from the 
analyser, they were not studied further. 
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Fig. 5.1 Mass spectrum of the brown-coloured crystals produced from ethyl-acetate extract of 
the culture fluid of strain N8.  
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Fig. 5.2 Mass spectrum of the needle-like pink-yellow crystals produced from the ethyl-acetate 
extract of the culture fluid of strain N8. 
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Fig. 5.3 Proton nuclear magnetic resonance (
1
H-NMR) analysis of the antimicrobial compound produced by strain N8. Note the portion of the spectrum 
showing evidence of one or two aromatic protons
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Fig. 5.4 Gradient correlation spectroscopy spectrum of the antimicrobial compound produced by strain N8 
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Fig. 5.5 Gas chromatogram of the antimicrobial substance in the ethyl acetate extract (EAF) after extraction of the culture fluid of strain N8. 
Components A – G were subjected to mass spectroscopy analysis. Note the occurrence of a possible tryptamine structure (G) and is essential for 
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Table 5.1 Compounds identified* by mass spectroscopic data analysis following gas 









Mol. formula Index name of compound Prob. 
(%) 
A 6.93 98 C6H10O  3-hexen-2-one 
 4 methyl-4-penten-2-one 
37 
11 
B 8.06 98 C6H10O  3-hexen-2-one 
 4 methyl-3-penten-2-one 
20 
39 
C 8.99 116 C6H12O2  4-hydroxy-4-methyl-2-
pentanone 
57 
D 14.02 138 C9H14O  2,6-dimethyl-2,5, 
Heptadien-4-one 
57 






F 23.05 296 C21H44  10-methyl elcosane 
      (alkane hydrocarbon) 
6 








* Identification based on the built-in computer database of known compounds [National Institute of 
Standards and Technology (NIST), www.nist.gov]. 
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Fig. 5.6 Structural identity of component G: A, Full mass spectrum of component G; B,  







                             
 
N-[2-(1H-indol-3-yl) ethylacetamide (=N-acetyltryptamine)         Melatonin 
 
Fig. 5.7 The tentative structure of the antimicrobial compound produced by strain N8. A, 
Structure of N-acetyltryptamine; B, Melatonin 
 
5.4 Discussion 
The LC-MS spectrum of the pink-yellow crystals showed evidence of a base/prominent 
peak at 304.2724 m/z in positive mode (Fig. 5.2). The base peak in a mass spectrum 
corresponds to the separated ion beam which has the greatest intensity. The elemental 
composition of the compound that yielded this base peak suggests a molecular formula 
closely similar to C16H36N2O3 with a molar mass of 304.4686 g/mol. However, the 
compound could be assigned a name from the databases of natural compounds 
[National Institute of Standards and Technology (NIST), www.nist.gov].  
 
On further analysis of the pink yellow crystals MS data it became evident that the 
metabolite is not pure since bands appear at a range of masses above 304. The 1H- 
and GCOSY- nuclear magnetic resonance (NMR) spectroscopy (Fig. 5.3 and Fig. 5.4  
respectively) profiles of the crystals appear to have some properties of tryptamine in 
them but mixed with another compound making it impossible to assign a single 
structure based on these profiles. 
 
However, when the GC-MS profile of the antimicrobial substance produced by strain 
N8 was compared to MS profiles from the databases of natural compounds, a better fit 
was obtained with 71% probability of being accurate. GC-MS is the single most 
important tool for the identification and quantification of organic compounds in complex 
mixtures (Santos and Galceran, 2002). GC-MS analysis of strain N8 metabolite 





represent two similar molecular compounds (possibly isomers) since they have the 
same molecular weight and formula. Their different retention indices strongly suggest 
that they are indeed isomers. In a GC-MS, the lighter molecules elute first followed by 
heavier molecules (Krupp and Donard, 2005). It is evident from the GC-MS results that 
G is the heaviest molecule since it eluted last from the column. It has a molecular 
formula of C12H14N2O with a structure that closely resembles an indolethylacetamide 
(=N-acetyltryptamine) [Fig. 5.7A]. The 71% probability (Table 5.1) refers to how closely 
the structure of the compound in question matches the index value from a chemical 
structure library or a computer database of known compounds [National Institute of 
Standards and Technology (NIST), www.nist.gov].  
 
The structure of component G (N-acetyltryptamine) was compared to structures of 
commonly used antibiotics (Refer to Fig. 1.2, Chapter 1) in an attempt to tentatively 
suggest its mode of action. N-acetyltryptamine has been reported to be produced by 
both Thermoactinomyces strain TA66-2 (Korkmaz et al., 2008) and Streptomyces 
species strain TN58 (Raoudha et al., 2009). Thiazole was also reported to be produced 
simultaneously with N-acetyl tryptamine by the above mentioned authors. Tryptamine is 
a monoamine alkaloid found in plants, fungi, and animals. It is based around the indole 
ring structure, and is chemically related to the amino acid tryptophan, from which its 
name is derived. Tryptamine is found in trace amounts in the brains of mammals and is 
believed to play a role as a neuromodulator or neurotransmitter. Tryptamine is also the 
backbone for a group of compounds known collectively as tryptamines. This group 
includes many biologically active compounds, including neurotransmitters and 
psychedelic drugs (Jones, (1982).  
 
A closely related structure is known as melatonin (Fig. 5.7B) which has been attributed 
with the ability to inhibit tumour growth in vivo and in vitro. Recent studies have shown 
that melatonin can profoundly retard tumour progression induced by chemical 
carcinogens and can also modulate enzymes involved in xenobiotic metabolism and 
detoxification (Tan et al., 1993). An example of a group of enzymes involved in 
xenobiotic metabolism is hepatic microsomal cytochrome P450. These enzymes that 
metabolize xenobiotics are very important for the pharmaceutical industry, because 
they are responsible for the breakdown of medications. Melatonin is also known for its 
radical scavenger activity, which had been related to its ability to protect neuronal cells 




combination with other agents, has been studied for anticarcinogenic or carcinostatic 
activity against a variety of human cancers (Lissoni et al., 1987). 
 
The antibiotic produced by strain N8 appears to be a mixture of closely related 
compounds the main component of which is shown in Figure 5.6A with a peak at 143.1 
m/z (M + Na+). A feature of the antibiotic is the occurrence of a tryptamine structure 
and is essential for antimicrobial activity (Korkmaz et al., 2008; Raoudha et al., 2009). It 
is postulated that the antibiotic produced by strain N8 shares the same mechanism of 
action with tryptamine.  
 
5.5 Conclusion 
The chemical nature of the antibiotic produced by Intrasporangium strain N8 was partly 
revealed by the results of the GC-MS analysis. However, the true chemical identity of 
the antibiotic could not be confirmed by comparison with any known compounds in the 
database of natural products available. More work involving additional chemical 
analytical techniques is required to conclusively prove its novelty. This however, is 
beyond the scope of the present investigation which is essentially microbiological. The 
indications are that the antibiotic is a tryptamine, the tentative structure of which is 
shown in Figure 5.7. To the authors knowledge no known antibiotic produced by 





ANTIMICROBIAL EFFICACY OF COMPOUND(S) PRODUCED BY 
INTRASPORANGIUM STRAIN N8  
 
6.1 Introduction 
The use of a single antibiotic in the initial treatment of infectious diseases has 
continued for many, many years. This strategy has too often resulted in strains showing 
induced resistance to the antibiotic. As new antibiotics are discovered, the 
microorganisms keep inventing new ways of becoming resistant to them. The 
development of resistance easily outpaces the appearance of new antibiotics (Fox, 
2007). 
 
There are many reasons for using a combination of two or three antibiotics with 
different mechanisms of action in the initial treatment of infectious diseases. (1) At 
normal mutation rates the chances are infinitesimally small that two or three resistance 
mutations will occur spontaneously against two or three antibiotics with different 
mechanisms of action; (2) It has been shown that “the effect of combined antibiotics in 
serum attainable levels is bactericidal as opposed to the ineffectiveness of the 
maximum dosage of each antibiotic when given singly” (Balows,  2006); (3) A 
combination of the most pharmaco-dynamically effective members of an antibiotic 
class, reduces the duration and overall costs of a disease treatment, due to fewer 
relapses and follow-up therapy for patients contending with an antibiotic resistance 
problem (Scheld, 2003a). 
 
A typical example of combination therapy is the use of Rifater antibiotic. Rifater is a 
triple combination antibiotic of isoniazid, rifampicin and pyrazinamide. Use of a triple 
combination antibiotic to treat tuberculosis became necessary because isoniazid which 
was used for many years to treat TB (mostly in Southeast Asia) eventually became 
ineffective since TB strains became resistant to it. Rifater was formulated in an attempt 
to try to prevent TB strains from becoming resistant to rifampicin and/or pyrazinamide. 
Ethambutol was also added to the anti-TB regimen (Hibbard, 2007). 
 




at a time and combination therapy was not used; a few strains of Mycobacterium 
tuberculosis eventually became resistant to all TB therapies. In the Rifater clinical 
studies, the combination of the three antibiotics mentioned above did not result in any 
more adverse contraindications in patients than when each antibiotic was given 
separately. If each antibiotic has a different mechanism of action, it seems logical that 
the adverse effects due to each antibiotic would be independent of one another 
(Hibbard, 2007). 
 
The aim of this part of the study was to optimize the efficacy of the antibiotic produced 
by Intrasporangium strain N8. The six compounds identified during GC-MS analysis 
were not recoverable due to the nature of the equipment used so it was not possible to 
conduct further tests on each of them individually. However, three major compounds 
(peaks) were successfully collected and purified by GHPLC analysis for this part of the 
study. The compounds (peaks) viz. PI, PII and PIII were tested against major plant and 
human pathogens both singly and in various combinations to see whether they are 
biologically more effective when combined than when used separately. The results 
were compared with some standard antibiotics. 
 
6.2 Materials and Methods 
6.2.1 Test media 
All media used were prepared in distilled deionized (DI) water. Mueller-Hinton (MH) 
medium (Beef extract, 2g; Casein hydrolysate, 17g; Starch, 1,5g; Agar, 17g; per litre 
(pH 7.4) was used for susceptibility testing. 
 
6.2.2 Target microbes 
The test organisms were all from the culture collection in the Discipline of Microbiology, 
University of KwaZulu-Natal as described in Section 2.5. Micrococcus luteus (ML), a 
human pathogen and two unidentified endogenous bacterial pathogens of Eucomis 
autumnalis autumnalis (Eaa) and Veltheimia bracteata (Vyb) were added to the list. 
The fungal pathogen of potato, Rhizoctonia solani (Rhz) was also tested. The 
unidentified organisms were supplied by UKZN‟s Plant Pathology Department. Eucomis 
autumnalis autumnalis commonly known as „pineapple flower‟ is used medicinally in 




„Yellow flame‟ is touted to have a purgative effect. 
 
6.2.3 Recovery and purification of the antimicrobial agent 
All major steps used in the recovery procedure are shown in Figure 2.2 and described 
in Section 2.12. The compound(s) was purified using GHPLC as described in Section 
2.13.4. Corresponding individual peaks were pooled from several HPLC runs of the 
sample and concentrated before bioassay. 
 
6.2.4 Bioassay  
The peaks used for susceptibility tests were collected from the GHPLC analysis. The in 
vitro antimicrobial activities were determined by agar disk-diffusion as described in 
Section 2.9.2. All samples were suspended in a minimal volume of methanol which 
was also used as the control. Some standard antibiotics, namely, Penicillin G (10 i.u.), 
Bacitracin (10 i.u.) and Tetracycline (10 mcg), supplied by Oxoid, and an unidentified 
locally produced antimicrobial agent (V3)* were used in order to compare the results 
with those obtained with the antibiotic compounds produced by N8. The standard 
antibiotics used are secondary metabolites of three major antibiotic-producing groups 
of microorganisms, viz. moulds, eubacteria and actinomycetes. The minimum inhibitory 
concentration was determined by broth micro-dilution methods according to the 
protocol recommended by the Clinical and Laboratory Standards Institute (CLSI) 
[formerly National committee for clinical laboratory standards (NCCLS)] as described in 
Section 2.9.3. The MIC of the mixture (PPM) was compared to that of the individual 
components, PI, PII and PIII. Synergy in this study referred to instances where the 
average diameter of the inhibition zone was greater, or the MIC was less, for the 
combined peaks than was the average inhibition zone diameters, or MICs, of the 
individual peaks when tested separately.  Contrary to the above instance where the 
MIC for the combined peaks was more than was the single peaks, it was referred to as 
antagonistic. A flowchart showing the steps used to test the efficacy of the GHPLC 
separated peaks obtained from the antibiotic produced by Intrasporangium strain N8 is 
shown in Figure 6.1. 
 
__________________________ 







Fig. 6.1 Flowchart showing steps used to test the efficacy of the gradient high performance 
liquid chromatography separated peaks obtained from the antibiotic produced by 
Intrasporangium strain N8. 
 
6.3 Results  
During primary screening, Intrasporangium strain N8 inhibited all the test organisms 
used on both NA (Fig. 3.1A) and ISTA plates (Fig. 3.1B) as described in Chapter 3. 
After extraction of the fermentation broth of the organism with various solvents (section 
2.12.2), all the extracts, with the exception of petroleum ether extract (Fig. 4.2C) 
showed good antimicrobial activity against the test organism as described in Chapter 
























further analysis. Purification of the EAF with GHPLC resulted in three peaks (PI, PII 
and PIII) [Fig. 4.5C] collected with an automated fraction collector (section 2.13.4).  
 
Results from growth-inhibition efficacy testing of the individual peaks showed that they 
induced different responses in the different test organisms (Fig. 6.2; Table 6.1). For 
example, PII (targeted and collected as pure during GHPLC analysis) showed clear 
inhibitory activity against E. coli (Fig. 6.2C) with average inhibition zone diameter of 
12mm and an MIC of 0.031μg/ml (Table 6.1). It also showed growth inhibitory activity 
against S. marcescens (15 mm) [Fig. 6.2A], X. campestris pv. campestris (12 mm) 
[Fig. 6.2B] and S. aureus (15 mm) [Table 6.1]. Likewise, PI inhibited the growth of E. 
coli (11 mm), X. campestris pv. campestris (11 mm) but showed no activity on S. 
marcescens (Table 6.1). The presence of resistant cells was observed when PIII was 
tested against S. marcescens (Fig. 6.2A). The average inhibition zone diameters 
together with the MIC results of the individual peaks on each of the test organisms are 
shown in Table 6.1. 
 
In an attempt to check for synergy, the individual peaks were tested along with 
combinations of two peaks (e.g. PI +PII mix) on different test organisms. The results 
showed that the individual activities of the peaks were minimal compared to when they 
were combined. For example, when PI and PII were combined, the diameter of the 
inhibition zone on plates inoculated with S. marcescens (Fig. 6.2A) was double (30 
mm) that produced by PII alone (15 mm). Likewise, a combination of PI and PIII on X. 
campestris pv. campestris (12 mm) showed inhibitory activity as compared to the little 
or no inhibition observed when PIII alone was tested (Fig. 6.2B). The mixture of PII and 
PIII did not inhibit the growth of most test organisms. The spectra of activities produced 
by individual and combined peaks against Gram-postive and Gram-negative test 
organisms are graphically represented in Figure 6.3A and 6.3B respectively. 
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Table 6.1 Antimicrobial activities of individual and combined peak(s) produced by Intrasporangium strain N8 against test organisms 
compared to standard antibiotics 
Test organism* Average Inhibition zone diameter (mm) MIC (µg/ml) 















PI PII PIII PPM 
Gram-positive organisms                
Staphylococcus aureus 18 15 12 23 nt uns 38 uns 28 uns 16 0.25 0.13 >1.0 0.0078 
Enterococcus faecalis uns uns uns 06 05 uns 22 uns 14 >1.0 >1.0 uns uns uns 0.25 
Micrococcus luteus 15 10 13 22 25 19 35 uns 25 uns uns 0.25 0.50 nt 0.02 
Gram-negative organisms                
Escherichia coli 11 12 uns uns uns nt 25 uns 05 uns 16 0.50 0.031 uns 0.039 
Pseudomonas fluorescens uns uns uns uns 20 rs 30 uns uns uns uns uns uns uns 0.063 
Serratia marcescens uns 15 15
rs
 30 nt 12 28 uns uns uns 0.13 uns 0.25 uns 0.125 
Xanthomonas campestris pv. campestris 11 12 uns 22 12 nt 25 uns uns uns uns 0.03 0.06 uns 0.002 
Yeast                
Candida utilis uns uns 14 uns uns uns 27 uns uns uns uns uns uns 0.25 0.002 
Plant pathogens                
Eucomis autumnalis autumnalis pathogen 12 13 17 11 nt 12 30 uns 30 uns uns 0.13 0.13 nt 0.06 
Veltheimia bracteata pathogen uns uns uns uns uns uns uns 30 uns uns uns uns uns uns uns 
Fungi^                
Rhizoctonia solani uns uns uns uns uns uns uns uns uns uns uns uns uns uns uns 
                
*Cultured on MH agar for disk diffusion or in MH broth for MIC determination; ^ cultured on PDA; uns, unsusceptible; nt, not tested; rs, resistant strains; 
Pen, penicillin; Bac, bacitracin; Tet, Tetracycline.
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Fig. 6.2 Growth inhibition of test organisms by individual and combined components of the 
antibiotic produced by strain N8. A, Inhibition of Serratia marcescens (Sm) [note the larger 
inhibition zone produced by the PI+PII mixture (30mm) than that produced by PII (15mm) 
alone and note also the presence of cells resistant to PIII]; B, Stronger inhibition of 
Xanthomonas campestris pv. campestris (Xc) by the combined action of PI+PII and also 
PI+PIII compared to the inhibition caused by each component separately; C, Inhibition of 























Fig. 6.3 Spectra of antibacterial activities of individual and combined peaks obtained from the 
antibiotic produced by Intrasporangium strain N8 against the test organisms: A, Gram-positive test 







As a sequel to the above analysis, all the peaks (PI +PII +PIII) were combined to check 
for improved efficacy against the test organisms. The peak-peak-peak mixture (PPM) 
showed strong growth inhibition against most of the test organisms (Fig. 6.4). For 
example, it strongly inhibited the growth of S. marcescens (Fig. 6.4A), S. aureus (Fig. 
6.4B), Pseudomonas fluorescens (Fig. 6.4C), and Micrococcus luteus (Fig. 6.4D) but 
failed to inhibit the growth of the fungal pathogen of potato, Rhizoctonia solani (Fig. 
6.4E). The diameters of inhibition zones observed were large [ranging from 28 mm for 
S. marcescens to 38 mm for S. aureus (Fig. 6.4)] compared to those produced by the 
individual components in the foregoing experiment. 
 
Graphical analysis of the peaks bioassay results showed a reduction in the MIC values 
required to inhibit the test organisms when the peaks were combined as compared to 
when used individually (Fig. 6.5). This synergistic effect was evident from the plot of 
the combined peak MICs which lies below the plot of the average and single peak MIC 
values (Fig. 6.5). For example, the inhibitory effectiveness of PI (Fig. 6.5A) was less 
than the combined peak effect for most of the test organisms except for X. campestris 
pv. campestris where both showed good inhibitory effect with MIC,s of 0.03µg/ml and 
0.002µg/ml respectively. Likewise, the inhibitory effects produced by a combination of 
the peaks (PI+PII+PIII) were by far better than the effect produced by PIII alone (Fig. 
6.5C) on most of the test organisms. In some instances, the combination produced an 
antagonistic effect with a higher MIC value than that obtained for a single peak. For 
example, the MIC for E. coli (0.039 µg/ml) using PII (Fig. 6.5B) was less than that 
obtained for the combined peaks with an MIC of 0.031µg/ml). A graphical analysis of 
single and synergic inhibition of plant and human pathogens by peak(s) produced by 
Intrasporangium strain N8 is shown in Figure 6.5. 
 
The inhibitory potential of PPM was then compared to standard antibiotics on MH agar 
medium. The inhibition of the pathogen of Eucomis autumnalis autumnalis (Eaa) by 
PPM is similar to that shown by commercial penicillin G (Fig. 6.6A). The unidentified 
antibiotic, V3, did not inhibit the growth of any of the test organisms except the yellow 






   
 
Fig. 6.4 Efficacy of PPM (PI+PII+PIII Mix): A - E = Synergic inhibition of plant and human 
pathogens by PPM. Test organisms include: A, Serratia marcescens (Sm); B, Staphylococcus aureus 
(Sa); C, Pseudomonas fluorescens (Pf); D, Micrococcus luteus (ML); E, Rhizoctonia sp. (Rhz) a fungal 













Fig. 6.5 Graphs showing single and synergic inhibition of plant and human pathogens by 
peak(s) produced by Intrasporangium strain N8: A, Peak 1 (PI); B, Peak II (PII); C, Peak III (PIII). 
Sa, Staphylococcus aureus; Ef, Enterococcus faecalis; Ml, Micrococcus luteus; Ec, Escherichia coli; Pf, 
Pseudomonas fluorescens; Sm, Serratia marcescens; Xcc, Xanthomonas campestris pv. campestris; 







   
Fig. 6.6 Growth inhibitory efficacy of PPM (PI+PII+PIII Mix) compared to that of penicillin (Pen) 
and an unidentified antimicrobial substance (V3) supplied by UKZN Plant Pathology Department 
against A, an unidentified bacterial pathogen of Eucomis autumnalis autumnalis (Eaa), and B, 
an unidentified pathogen of Veltheimia bracteata (Vyb); Pen, Penicillin G. Note similar activities 
of PPM and penicillin. 
 
MIC determinations conducted in MH broth showed that in general the mixture (PPM) 
had a higher inhibitory activity than the individual components (Table 6.1). For 
example, the MIC for PPM against Staphylococcus aureus was 0.0078µg/ml whereas 
the MICs for the individual components ranged from 0.13µg/ml to >1.00µg/ml. PPM 
generally showed a strong inhibitory activity against the Gram-positive test bacteria, the 
exception being Enterococcus faecalis which was only weakly inhibited (MIC = 
0.25µg/ml). A strong inhibitory activity was also observed against the Gram-negative 
test bacteria Pseudomonas fluorescens (0.063µg/ml), Serratia marcescens 
(0.125µg/ml) and Xanthomonas campestris pv. campestris (0.0025µg/ml). The two 
unidentified plant pathogens were less sensitive to the individual components (PI, PII 
and PIII) than to the combination (PI+PII+PIII). Of note is the inhibitory spectrum of PIII 
which showed minimal activity against all the bacteria tested but was active against the 
yeast, Candida utilis (0.25µg/ml). None of the individual components showed any 
activity against Pseudomonas fluorescens. In the case of the fungal plant pathogen 
Rhizoctonia solani, neither the components nor the mixture showed any inhibitory 
action. A summary of the antimicrobial activities of the antibiotic produced by 







Testing for synergy often requires the use of pure compounds. To obtain such 
compounds usually involves many purification steps which can be a very challenging 
task, particularly if the sophisticated instrumentation required for the task is not 
available. To achieve 100% purity may not be possible, and hence less pure 
compounds may be used initially. 
 
However, a brief mention of the efforts expended to obtain a pure compound for the 
synergy tests will give some idea of the scope of the present study. The antimicrobial 
agent of interest was extracted with ethyl acetate and alcohol but was not extractible 
with petroleum ether. This suggested that it was possibly a polar organic compound. 
Having established that the substance was extractible with a polar solvent, the next 
step involved purification since it could be a mixture of several compounds. 
 
To this end, thin layer chromatography (TLC) was employed and revealed the 
presence of three bands on the chromatogram. Two identical aluminum-backed silica 
TLC plates overlaid with a thin layer of MH agar were sprayed separately with the test 
organisms E. coli and S. marcescens and observed for inhibition. These organisms 
were chosen because they showed susceptibility during primary screening. The 
bioautograms obtained were not conclusive on these plates but subsequently much 
better results were obtained when plastic-based silica TLC plates were used. Much 
effort was expended in standardizing the bioautogram procedures which were 
problematic since the equipment for spraying the test organisms onto the plates was 
difficult to quantitate as was standardisation and optimisation of the thickness of the 
agar overlay. Diffusion and concentration of the antibiotic compound(s) were major 
factors in assessing the practicality of the bioautogram technique. For example, 
substances separated on the chromatogram could be bound to the silica plate 
depending on their polarity thereby hindering the diffusion of the antibiotic into the agar 
growth medium. 
 
Therefore extraction was carried out by scraping the silica off duplicate plates at 
positions corresponding to the bands on the initial chromatogram and eluting with ethyl 
acetate as described in Section 2.13.2, Chapter 2. At this stage, further biological 
activity testing was carried out using either broth micro-dilution or agar-disk diffusion 




consumed. The numbers of bands eluted per solvent system are shown in Appendix 1.  
Based on the bioassay results, attention was focused on the ethyl acetate extract 
which was further purified by HPLC. Corresponding peaks were pooled from several 
runs to obtain sufficient amounts of the compounds for bioassay. 
 
The compounds used for synergy tests were separated by gradient HPLC to a high 
level of purity. Initially, individual fractions eluting at 1 min intervals were assayed on 
the test organisms. Unfortunately, the results of these bioassays were not conclusive, 
possibly as a result of dilution of the antibiotic compound. Corresponding fractions from 
several repeat runs were then pooled to increase the concentration of the putative 
active substances before bioassay.  
 
The larger diameters of the inhibition zones obtained following mixing of the 
compounds (PPM) indicated a stronger inhibition of the test organisms, suggesting that 
they were more susceptible to the combination than to the individual substances. The 
reason may be that with the mixtures the test organisms were hit simultaneously at 
different sensitive targets in the cell thus enhancing the inhibitory action of the 
compounds. Alternatively, uptake and transport of the active compound within the cells 
is enhanced by the presence of the other substances. Two or more different targets 
inside the cell may be adversely affected and this may mean that more than one 
mechanism of action is involved (Yeaman and Yount, 2003; Balows, 2006).  
 
Both PPM and penicillin G inhibited the growth of the bacterial pathogen of Eucomis 
autumnalis autumnalis (Eaa) but failed to inhibit the growth of the pathogen of 
Veltheimia bracteata (Vyb) under standardized conditions suggesting they had similar 
modes of action. The target site of these two antibiotics could be the same which may 
or may not, be essential to the growth of the two test organisms respectively. The major 
substance in PPM indicated a structure related to the peptide class of antibiotics while 
penicillin G is a β-lactam antibiotic. Both classes, however, have similar modes of 
action in that they inhibit steps in peptidoglycan biosynthesis and murein assembly 
(Franklin and Snow, 1981; Todar, 2009).  
 
The MIC results shown in Table 6.1 serve as an index of the antimicrobial spectra of 
the components of the antibiotic produced by Intrasporangium strain N8. Of note is the 




when determined by the broth micro-dilution or agar-diffusion techniques. The reason 
is that the MIC determinations were done in a liquid medium without agar. Agar with its 
SO3
- groups can absorb antibiotics, thus changing the conditions for diffusibility of the 
antibiotic, of dissolved oxygen, and of nutrients (Lancini et al., 1995). 
 
It is clear from the MIC results that strain N8 produces a broad-spectrum antibiotic with 
inhibitory activity against prokaryotes including both Gram-positive and Gram-negative 
bacteria and against the eukaryotic yeast Candida utilis. The antifungal activity of the 
antibiotic could not be confirmed conclusively as it failed to show significant inhibitory 
activity against the fungal pathogen, Rhizoctonia solani. A further test on additional 
fungal pathogens is required to confirm its fungicidal capabilities. 
 
To date, information on the genus Intrasporangium is sparse, and to the author‟s 




The synergistic inhibition of S. marcescens by a combination of PI and PII, together 
with the results obtained with different combinations of P1, PII and PIII on various test 
organisms, especially Pseudomonas fluorescens and Xanthomonas campestris pv. 
campestris, showed that it was preferable to use combinations of the isolated 
compounds rather than any of the individual components singly for treatment of these 
serious agents of infectious plant diseases. Single antibiotic administration has been 
used for many years in the initial treatment of infectious diseases; a strategy that too 
often resulted in inducing resistance to the antibiotic in some strains. According to Fox 
(2007), development of resistance easily outpaces the appearance of new antimicrobial 
drugs on the market and, therefore, it is time to change our strategy for treatment of 
infectious diseases by using either appropriate combinations of the available antibiotics 







Most of the objectives set out at the beginning of this study have to some extent been 
successfully met. 
 
Initially, there was a strong belief that the microbiota inhabiting South African soils has 
the potential to produce new antibiotics judging from the successes achieved by 
Baecker and Ryan in 1987 and Wang et al. in 2006. Both reported that novel antibiotic-
producing soil-inhabiting, actinomycetes had previously been discovered in Natal 
habitats, viz. pimaricin and platencin respectively. 
 
It seemed reasonable to suppose that other genera and species producing new 
antimicrobial substances could be discovered. The literature showed that much work 
has been done by many scientists on actinomycetes, especially Streptomyces species, 
so the present investigation was designed to exclude Streptomyces spp. and target 
instead rare actinomycetes, also known as rare actinos. Thus a search for non-
streptomycetous, antibiotic-producing actinomycetes was undertaken in KwaZulu-Natal 
soils from areas never investigated before. The media used by earlier scientists like 
Waksman (Waksman et al., 1942) and Lechevalier (Lechevalier, 1989) to isolate 
actinomycetes were modified, based on current knowledge. These adaptations made 
the media more selective for the target organisms. The geographical distribution and 
antimicrobial activity of the organisms isolated is discussed in Chapter 3. 
 
Ten isolates showing antimicrobial activity against two or more of the seven test 
organisms used were studied further. The test organisms were selected on the basis of 
a 1999 survey of the most common animal and plant bacterial pathogens in KwaZulu-
Natal hospitals and the University vegetable gardens respectively. All ten of the 
producer organisms were tentatively identified to genus level. 
 
Of these ten organisms, one isolate stood out from the rest, viz. N8. It showed activity 
against all seven test organisms especially Pseudomonas fluorescens and 




field. The results of this aspect of the investigation have been published in a peer 
reviewed journal. 
 
Because of these useful attributes further studies on N8 were undertaken. The first 
step was to identify the organism using standard bacteriological methods. The 
organism was identified as an Intrasporangium species and given the appellation 
Intrasporangium strain N8. 
 
Next, an attempt was made to isolate and purify the antibiotic produced by N8. These 
processes were successfully carried out using solvent-to-solvent extraction procedures 
to separate the antibiotic from the culture broth followed by various chromatographic 
techniques. As these procedures were time consuming, required large volumes of 
solvents, and resulted in low antibiotic yields, they were replaced with a process 
entailing a combination of a three-solvent system and pH precipitation. 
 
Using this procedure, large enough quantities of the antibiotic were recovered from the 
fermentation broth to permit a degree of structural elucidation. 
 
The chemical nature of the antibiotic was successfully established by means of 1H- and 
nuclear magnetic resonance (NMR), liquid chromatography – mass spectrometry 
(LCMS) and gas chromatography – mass spectrometry (GCMS). The empirical formula 
was determined to be C16H36N2O3. At this stage, it became clear that a full structural 
elucidation of the compound(s) showing antimicrobial activity was a project on its own 
and thus beyond the scope of this thesis which is largely microbiological. 
 
For microbiologists, the chemical structure of antimicrobial compounds is of interest 
since it may indicate a possible mode of action of the substance. However, their 
biological activity and efficacy as growth inhibitors is more important. In chapter six, the 
inhibitory potential of the components of the antibiotic produced by strain N8 was 
examined. Data from the bioassay results demonstrated that the use of combinations 
of the components producing the individual peaks on the trace were significantly more 
effective than any of the single components when used alone, thereby providing 
evidence of synergistic action.  For example, the diameters of the inhibition-zones were 
doubled when a combination of the components PI and PII was used against both S. 





Genetic engineering is also recommended to improve the yield of the antibiotic 
produced by N8. The toxicity of the antibiotic produced by N8 should also be studied to 
establish its clinical significance. An extension of this study can be carried out on the 
use of N8 in agriculture by testing its efficacy in the field on a broader range of fungal 
and bacterial plant pathogens. This is important since the current trend is towards 
biocontrol using natural substances rather than synthetic chemicals to treat plant 
diseases. 
 
In conclusion, the initial objective of targeting rare actinomycetes was successfully met, 
leading to the isolation of Intrasporangium strain N8 and characterization of the 
antibiotic produced by the organism which has not been reported previously. However, 
further investigations mainly of a chemical nature and outside the scope of this thesis 
should be carried out to determine if the antibiotic produced by N8 is indeed novel. 
 
Hopefully, the results of this study will encourage renewed efforts in the search for 
novel antibiotics in South African soils. Owing to its spectrum of activity the antibiotic 
produced by N8 could, if found suitable for commercialization, impact on the 
pharmaceutical and plant protection industries for the treatment of both human/animal 
or plant infectious diseases, especially in sub-Saharan Africa. 
 
The following recommendations are made through the experiences gained during this 
investigation: 
 
 Obtaining unknown antibiotic compounds in pure form is laborious and time-
consuming. Careful consideration regarding the order in which chemical 
analyses are done is therefore essential. Investigators interested in the 
structure of the compound under study should begin with chemical analyses 
that do not consume the purified substance, i.e. NMR, LC-MS, before 
proceeding to bioassays and GC-MS analysis. This will eliminate the problem of 
running out of purified sample early in the investigation and will also save the 






 Improvement of strain N8 by genetic engineering is recommended to produce 
new strains with increased antibiotic production capacities. 
 
 The toxicity of the antibiotic produced by N8 should also be investigated to 
establish its clinical significance. 
 
 The usefulness of N8 in agriculture should be assessed by testing its efficacy in 
the field on a broader range of fungal and bacterial plant pathogens. 
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Appendix 1 Average Rf values* of bands on TLC chromatograms from solvent extracts 
of strain N8  
*average values from triplicate runs of samples on TLC chromatograms (Rf values calculated from distance traveled by 
spot divided by distance traveled by solvent). ^SS1= methanol: ethyl acetate (80:20); SS2= ethyl acetate: methanol 





No. of bands  per 
solvent system (SS)^ 
 







SS1             3 
SS2             4 







0.45; 0.55; 0.64 
0.03; 0.22; 0.46; 0.76 






SS1              3 













SS1              4 
SS2              4 





0.08; 0.64; 0.70; 0.79 
0.22; 0.27; 0.56; 0.64 
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Appendix 2 Line list for 
1
H-NMR of antimicrobial compound produced by 
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Appendix 3: The absorbance values of strain N8 during growth in Nutrient broth (  = 
550 nm) 
 
Time (hours) Absorbance Log (Absorbance) 
0.0 0.099 -1.004 
48.0 0.225 -0.648 
48.5 0.241 -0.618 
49.0 0.249 -0.604 
49.5 0.276 -0.559 
50.0 0.350 -0.456 
50.5 0.438 -0.359 
51.0 0.477 -0.322 
51.5 0.505 -0.297 
52.0 0.528 -0.277 
52.5 0.503 -0.298 
53.0 0.495 -0.305 
53.5 0.549 -0.260 
54.0 0.567 -0.246 
54.5 0.609 -0.215 
55.0 0.606 -0.218 
55.5 0.652 -0.186 
56.0 0.685 -0.164 
56.5 0.746 -0.127 
57.0 0.879 -0.056 
57.5 0.944 -0.025 
58.0 0.932 -0.031 
58.5 0.925 -0.034 
59.0 0941 -0.026 
59.5 0.964 -0.016 
60.0 0.904 -0.044 
 
 
